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EPIDEMIOLOGY, ECOLOGY, AND EVOLUTION OF CANINE INFLUENZA VIRUS H3N8 IN UNITED 
STATES DOGS 
 
 Canine influenza virus (CIV) first emerged in dogs at a Florida racing track in 2004, although 
serological evidence suggests the virus has been circulating in the Unites States since as early as 1999. 
Phylogenetic analysis shows that CIV isolates are related to equine influenza virus of the Florida Clade 1 
sublineage. However, sustained transmission of CIV among dogs and further genetic evolution of the 
virus has established CIV as a canine-specific influenza A virus (IAV). During the early years after 
emergence, studies determining the impact of CIV on dog populations were scarce. The few published 
findings were also alarming, with case fatality rates as high as 36% and seropositivity as high as 97% in 
certain dog populations. Despite these reports, the prevalence of CIV infection in dogs, the transmission 
dynamics among dog populations, risk factors for CIV infection, and how the virus was evolving within the 
canine host had yet to be examined. The research described here sought to fill these knowledge gaps by 
accomplishing four main objectives: (1) to evaluate diagnostic tests for detecting CIV infection in nasal 
swab samples and to determine which test(s) would be most sensitive for rapid and accurate CIV 
diagnosis, (2) to estimate the seroprevalence of CIV antibodies in several dog populations, including 
household pet, racing sled, and shelter dogs, and to evaluate any risk factors associated with CIV 
seropositivity, (3) to identify epidemiological and ecological determinants of CIV infection within U.S. 
shelter dogs, and (4) to determine the degree of genomic evolution and antigenic variability of CIV in U.S. 
dogs.  
 For the first objective, nasal and pharyngeal swab samples were collected from 124 shelter and 
household dogs seen at Colorado State University Veterinary Teaching Hospital (CSU VTH) for canine 
infectious respiratory disease between April 2006 and March 2007 and from 1372 dogs housed in six 
shelters from December 2009 to November 2010. Several methods – virus isolation, real time reverse 
transcriptase polymerase chain reaction (rRT-PCR), and rapid influenza detection tests (RIDT) – were 
used to detect presence of CIV in these samples and compared to determine which test was most 
sensitive. Using a stochastic latent class modeling approach, the median sensitivities of virus isolation, 
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Directigen Flu A+B®, and rRT-PCR were estimated at 72%, 65%, and 96%, respectively. Furthermore, a 
different RIDT, the Flu Detect™, performed poorly for detecting CIV nasal shedding compared to rRT-
PCR. 
 Objective two was addressed using data from three different studies. In the first study, to 
determine seroprevalence and risk factors for CIV in Colorado household dogs, serum samples from 140 
dogs presenting to the CSU VTH Community Practice service, 110 dogs seen at other clinical services in 
2009, and samples from 75 dogs seen prior to 2004 were tested with hemagglutination inhibition (HI) 
assay, using three CIV isolates. To identify risk factors for CIV infection, 140 owners completed 
questionnaires at the time of sampling. Results showed CIV seroprevalence was 2.8% (4/140) for dogs 
seen by the Community Practice service and 4.5% (5/110) for dogs seen by other hospital services. All 
sera collected prior to 2004 tested negative for CIV. No differences were seen in antibody titers to the 
three CIV isolates tested, suggesting that measurable antigenic drift had not yet occurred as of 2009. 
Data from questionnaires indicated an association between CIV seropositivity and canine day-care visits.  
 A similar study was conducted in sled dogs from the United States and Canada racing in the 
2010 Iditarod to determine the seroprevalence of CIV in the sled dog population. Questionnaires were 
completed detailing medical and CIV vaccination history, kennel size and location, travel history, and 
social interactions for each team. Three hundred ninety-nine dogs were tested for CIV antibodies by HI 
assay. Of these, including 39 samples from dogs reported as CIV vaccinated, none was seropositive for 
CIV antibodies. Furthermore, all of the vaccinated dogs were also negative on virus microneutralization 
assay. Although risk factors for CIV seropositivity could not be determined due to lack of positive 
samples, this was the first published study investigating the prevalence of CIV in sled dogs.  
 For the third study, which also sought to address the third objective, risk factors for both CIV-
shedding and CIV-seroprevalence in shelter dogs were examined, as well as transmission dynamics 
between shelter and community dogs. Nasal swab and serum samples were collected from over 5160 
dogs upon admission or discharge from six U.S. humane shelters from December 2009 through January 
2012. HI and rRT-PCR assays were performed for each nasal and serum sample, respectively. True 
prevalence was estimated by stochastic latent class analysis. Results showed that the New York and 
Colorado shelters had the highest numbers of both CIV nasal shedding and CIV seropositivity. 
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Differences in CIV rates upon intake and discharge depended on the humane shelter sampled. An 
information theoretic approach to model selection and multi-model inference were used to identify risk 
factors associated with CIV infection and seropositivity. These risk factor analyses suggest that CIV 
shedding and CIV seropositivity are associated with region, month, year and co-mingling/co-housing. 
Additionally, the number of days within a shelter was associated with CIV seroprevalence.  
 Finally, the last objective was addressed by a study focused on the evolution of CIV to determine 
if antigenic drift is occurring, especially since the widespread use of a recently developed killed CIV 
vaccine. To this end, the full-length hemagglutinin gene of 19 CIV isolates from dogs sampled from 
Colorado, New York, and South Carolina humane shelters were sequenced. Both the nucleotide and 
amino acid sequences were compared to all those published for CIV strains isolated since 2003. 
Phylogenetic analysis suggests that CIV is diverging into two genetically distinct clades. Using a mixed-
effects model for evolution (MEME), five amino acid sites were found to be undergoing episodic selection 
pressure: 107, 169, 216, 453, and 464. Additionally, a total of five amino acid changes were observed in 
two antigenic sites for CIVs isolated from the New York and South Carolina humane shelters between 
2009 and 2011 (H75Q, K172E, N216H, V223I, and P262T). Although preliminary data suggest that the 
New York clade is evolving into a distinct antigenic cluster, controlled experiments are required to 
determine true extent of antigenic drift occurring within circulating CIV. 
 In conclusion, the studies conducted here report several important findings that deepen our 
understanding of CIV. (1) Real-time RT-PCR assays should be used as a rapid test for detecting CIV and 
can minimize false negatives, allowing a more accurate depiction of CIV infection in dogs. (2) Both CIV 
shedding and seroprevalence in the dog populations sampled are not as high as reported in racing 
greyhounds during the first CIV outbreak in Florida, suggesting that there may be other genetic or 
environmental factors contributing to fatal CIV infection or that perhaps there are host-immune response 
mechanisms restricting severe CIV infection. (3) Despite low prevalence of disease, however, control 
measures should still be implemented for at-risk dogs, such as dogs in boarding facilities, attending 
canine day-care, and residing in humane shelters. (4) Additionally, CIV, like other influenza A viruses, 
appears to be a disease of space and time. Therefore, modeling could be helpful for predicting future CIV 
outbreaks. (5) Finally, CIV is evolving into two genetically distinct clades, one of which is antigenically 
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different from previous CIV isolates. Controlled experiments are required to determine true extent of 
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CHAPTER ONE: INTRODUCTION 
 
Background for this study 
 Influenza A viruses (IAV) are considered commensal pathogens of their reservoir waterfowl 
hosts.1 Occasionally, however, IAV is transmitted from aquatic birds to mammals and poultry, causing 
clinical disease and even death in infected individuals. While most cross-species IAV transmission events 
result in incidental infection, in which the virus is not further transmitted to naïve individuals, host-
adaptation does indeed occur, allowing the new IAV to spread efficiently among susceptible hosts.2 
Moreover, once an IAV becomes maintained within a species, host immune selection pressures further 
influence IAV evolution along a host-specific lineage. Human, equine, and swine IAVs are noteworthy 
examples of particularly successful avian-to-mammal transmission events, resulting in established host-
specific influenza lineages.1 Interestingly, horses suffered two such occurrences in the latter half of the 
20th century. In 1956, an H7N7 IAV was isolated from a horse in Prague.3 H7N7 viruses circulated in 
equids until 1980, when the last known H7N7 equine influenza virus (EIV) was isolated from an 
Yugoslavian horse.4 However, serological evidence suggests that H7N7 might still be circulating, as H7-
specific antibodies have been detected in unvaccinated horses as recently as 2004.5 The second 
transmission event was reported in 1963 after the isolation of an H3N8 IAV from a horse in Miami.6 It is 
from this latter EIV subtype that canine influenza virus (CIV) emerged in 2004.7 
 The advent of a canine-adapted IAV provided the perfect opportunity to examine mechanisms of 
species-specificity and to identify host range determinants that hinder transmission of IAV among 
species. In fact, early research in our laboratory was focused on this particular area (see Appendix A). 
However, it soon became apparent that little was known about CIV in naturally-infected dogs – the who, 
what, where, how, and why questions of an epidemiological study were still under investigation. Early 
reports indicated CIV infection resulted in high mortality and was highly infectious (capable of being 
spread from infected to susceptible dogs), as the case fatality rate of CIV-infected Florida racing 
greyhounds was 36%7 and shelters experiencing canine infectious respiratory disease (CIRD) had up to 
97% seropositivity among dog sera tested for CIV antibodies.7 Obviously, this new threat to canine health 
was cause for concern among veterinarians and dog owners, as well as to other health care practitioners 
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who were uncertain if CIV could be spread from dogs to their human companions.8 Our study, therefore, 
expanded to include a more diagnostic and surveillance-oriented approach for identifying the 
epidemiological and ecological factors that help to maintain canine-adapted IAV in dogs after cross-
species transmission. The overall goal of the research presented here was to examine the epidemiology, 
ecology, and evolution of CIV in U.S. dogs in order to advance our general understanding of how IAV 
jumps the species barrier. 
 
Objectives of research 
 There were four main objectives of my research. The first was to evaluate diagnostic tests for 
detecting CIV infection in nasal swab samples and to determine which test(s) would be most sensitive for 
rapid and accurate CIV diagnosis. For the second objective, we sought to estimate the seroprevalence of 
CIV in several dog populations, including household pet, racing sled, and shelter dogs, to better 
understand the extent of CIV infection within U.S. dog populations. Another part of this objective was to 
evaluate any risk factors associated with CIV seropositivity. The third objective was to identify 
epidemiological or ecological determinants of CIV infection within U.S. shelter dogs. Finally, for the last 
objective, we wanted to determine the degree of genomic evolution and antigenic variability of CIV in U.S. 
dogs. 
 
Main hypotheses of research 
 While there were several objectives for these studies, with individual aims (described in each 
subsequent section), there was one overarching hypothesis directing our research from the beginning: 
CIV is being transmitted and maintained within dog populations, resulting in the establishment of a 
canine-specific influenza A lineage. Although simple, it is important to note that EIV had been spread to 
dogs before9,10 and the mechanism that allowed EIV to adapt to the canine host and be transmitted 
among dogs is still unknown. If this hypothesis is correct, there are many implications, but several that 
pertain specifically to the following dissertation are (1) CIV prevalence may be different among canine 
populations, (2) such differences likely depend on CIV-associated ecological and epidemiological factors, 
and (3) as an IAV, CIV is potentially evolving genomically and antigenically within dogs. 
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Organization of dissertation 
 As each research chapter includes an introduction to the study’s relevant literature, Chapter 2 
consists of a brief literature review on influenza A viruses, in general, and the emergence of CIV, in 
particular. Following the literature review, five chapters (3-7) describe studies conducted from 2006 to 
2012. In Chapter 3, the specificities of tests use to detect CIV in swabs are estimated and compared 
using a stochastic latent class analysis (or Bayesian approach). Chapters 4 through 6 detail findings from 
surveillance studies to determine the prevalence of CIV in three different dog populations – Colorado 
household dogs, North American racing sled dogs, and dogs residing in shelters located throughout the 
U.S. – and to determine any risk factors associated with CIV in these populations. In Chapter 7, attention 
is re-directed to the evolution of CIV, with the characterization of genomic evolution and antigenic 
variation of CIV since emergence, and on how evolution might contribute to antigenic drift of the virus 
within dogs. Finally, in Chapter 8, conclusions and future directions are presented. One final research 
paper from early studies conducted in the Landolt laboratory describes a clinical study on EIV and CIV 
infection in dogs, as well as receptor-binding preferences for these viruses (included as Appendix A). 
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CHAPTER TWO: LITERATURE REVIEW 
 
Introduction to influenza A viruses (IAV) 
 Influenza A viruses belong to the family Orthomyxoviridae, which are negative-sense, single-
stranded RNA viruses. These segmented RNA viruses include five genera: influenza A, B, and C, 
Thogotovirus, and Isavirus.11 Influenza A viruses, the causative agents of pandemic influenza outbreaks 
such as the 1918 “Spanish flu” and 2009 “swine flu,” infect many mammalian and avian species.1 
Although other mammals have been infected with influenza B and C (namely, seals12 and swine,13 
respectively), viruses from these two genera primarily infect humans. Thogotoviruses are typically 
transmitted from ticks to mammals,14 while, isavirus (infectious salmon anemia) affects, as its name 
implies, salmonid species.15  
 The fact that influenza A viruses (IAVs) are segmented RNA viruses poses several problems for 
IAV outbreak prevention and control measures. Firstly, viral RNA-dependent RNA-polymerase necessary 
for transcription is inherently error-prone. For IAV, the rate of mutation is estimated to be 2 x 10-3 
nucleotide substitutions per position per virus generation,1 which may result in IAV immune escape if 
mutations are located in specific antigenic regions – a process termed antigenic drift.16 Annual influenza A 
vaccination is one strategy to counterbalance mutating IAVs in human populations.2 Secondly, whole 
gene segments may be exchanged among IAV isolates, known as antigenic shift,16 as was most recently 
seen in the latest influenza A H1N1 pandemic of 2009. In this case, a quadruple gene reassortment 
occurred among avian, swine, and human IAVs.17 With eight gene segments, two IAVs, theoretically, 
have the potential to reassort and generate 256 (28) new viruses. 
 
Virion structure 
 The IAV virion, which can be either spherical, elongated, or filamentous in shape,18 contains an 
outer lipid membrane (the envelope of the virus), two surface glycoproteins (trimeric hemagglutinin [HA] 
and tetrameric neuraminic [NA] proteins) which accumulate around lipid rafts, a tetrameric integral protein 
(matrix 2 [M2]) which functions as an hydrogen ion-channel, and the matrix 1 (M1) protein located on the 
underside of the lipid membrane.11 The M1 protein contributes to the virion structure by adding rigidity to 
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the lipid membrane.19 In addition, M1 is associated with the eight internal panhandle-shaped IAV 
ribonucleoproteins (vRNPs), which are formed by viral RNA (vRNA), nucleoprotein (NP), and the 
heterotrimeric polymerase complex (polymerase acidic [PA], polymerase basic 1 [PB1], and polymerase 
basic 2 [PB2] proteins).20 The two viral surface proteins (HA and NA) have been shown to play essential 
roles in antigenicity of IAV.21,22 To date, 17 HAs and 10 NAs have been identified (the latest HA and NA 
were recently isolated from Guatemalan fruit bats23). The HA and NA designate the IAV subtype. 
Although nearly all HA and NA subtypes have been found in waterfowl species, the reservoir for IAV, only 
specific HA and NA subtypes have been isolated from non-avian hosts. For example, recently circulating 
human IAV are subtype H1N1 or H3N2.22 IAV isolates from equids since 1956 have been primarily H7N7 
(1963-1980)3,4 and H3N8.6,24 Interestingly, IAVs from bats before the isolation of a distinct bat-lineage 
influenza virus (H17N10) were often contemporary human subtypes.25,26  
 
Cell entry and membrane fusion 
 Binding of the virus to a host cell involves sialic acid receptors on the surface of the host cell 
(respiratory epithelial cells for mammals and birds, as well as gastrointestinal epithelial cells for birds) and 
a receptor binding pocket on the viral HA surface protein, which, in the HA subtype 3 (H3) numbering 
system, includes amino acid residues 226 through 228.27 Viral attachment to cellular sialic acid (SA) 
receptors depends on the linkage of host cell oligosaccharides to SA,28 as well as on the biochemical 
structure of the SA itself (e.g., N-acetylneuraminic [Neu5Ac] or N-glycolneuraminic [Neu5Gc] acids).29 It 
has long been recognized that avian and equine influenza viruses preferentially bind to receptors that 
have a SA linked to a galactose (gal) residue by an α2,3 linkage, while human lineage viruses prefer 
α2,6-linked receptors.27,30-32 Additionally, receptor specificity has been found to correlate with the 
availability of the SA receptors within the host animal respiratory tract.9,33-37 
 IAV enters cells via the apical surface of epithelium, where host cell SA receptors are located. 
Interestingly, human viruses preferentially attach to non-ciliated human epithelial cells while avian viruses 
prefer to bind to ciliated cells.38 Viral entry is mediated by clathrin-coated endocytosis, although non-
clathrin non-caveolae endocytosis has also been reported.39,40 Fusion between the viral and endosomal 
membranes requires cleavage of the HA0 precursor by endogenous proteases41-43 into the two subunits 
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HA1 and HA2. The low pH (5-6) within the endosome results in a conformational change in the newly 
formed HA2 N-terminal fusion peptide, promoting insertion of the hydrophobic N-terminus into the 
endosomal membrane to modulate fusion with the viral membrane.44 
 Several models have been proposed to describe the next steps during membrane fusion.45 The 
stalk-pore hypothesis46,47 involves the creation of a fusion pore by the refolding of the coiled α-helices of 
the HA while the two different HA subunits are attached to the two different membranes (i.e., HA1 to the 
viral membrane and HA2 to the target or endosomal membrane), leading to the formation of a stalk which 
eventually narrows into a breakable hemifused diaphragm. Another model48,49 suggests that an oligomeric 
ring-like structure is formed by the HA trimers, resulting in a breakable proteinaceous bridge. Yet another 
alternative model50 hypothesizes that the fusion peptide is not inserted into the endosomal membrane, 
but rather into the viral membrane, causing HA refolding and formation of a dimple that extends to the 
endosomal membrane. Whatever the mechanism, the end result is the same: fusion of the viral envelope 
and endosomal membranes. This fusion event triggers the uncoating of the virus, which results in 
dissociation of vRNPs from the M1 protein and subsequent release of vRNPs into the cytoplasm.  
 
Viral replication and transcription 
 Because the virion requires host nuclear cell machinery for splicing the M and nonstructural (NS) 
genes into two transcripts each,11 nuclear import of vRNPs is required. Active transport through nuclear 
pore complexes (NPCs) requires nuclear localization signals (NLSs).51 Although NLSs have been found 
on the M1, polymerase, and the NS2 (also called the nuclear export protein or NEP) proteins, the NLSs 
on NPs (which bind ~24 viral RNA nucleotides per NP), are perhaps the most important.11 In general, 
NLSs contain binding sites for importin (karyopherin) α, which in turns binds importin β. Interestingly, the 
subtype of cellular importin α has been found to contribute to species-specificity.52 The NP-importin 
complex docks at the NPC and, in the presence of ATP and Ran-GAP, is translocated via cytoplasmic 
Ran-GTP.51 Viral RNA then undergoes transcription to messenger (m)RNA or replication from 
complimentary (c)RNA. 
 Both vRNA transcription and replication involves a vRNA promoter, consisting of the vRNA 5’ and 
3’ ends base-paired to one another, and the viral RNA-dependent RNA polymerase. Transcription of 
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vRNA requires a capped pre-mRNA fragment that functions as a primer. The cap is snatched by PB253 
and cleaved by PA.54 The addition of a guanosine to the 3’ end of the capped primer pairs with the 
penultimate cystine residue on the 3’ end of the vRNA, initiating vRNA transcription.11 PB1 then catalyzes 
each nucleotide.55 Termination occurs ~17 nucleotides from the 5’ end of the vRNA and a poly(A) tail is 
added onto the mRNA transcript. The cap and poly(A) tail are essential for mRNA nuclear export to the 
cytoplasm and subsequent translation.51 Unlike during transcription, vRNA replication requires the 
synthesis of encapsidated positive-sense cRNA in a primer-independent manner. The newly formed 
cRNA is a full-length complementary copy of the vRNA template.11 vRNA is then synthesized from cRNA, 
using the complementary cRNA promoter, and eventually packaged with NP, PA, PB1, and PB2 proteins 
to make up the vRNP, which then associate with M1 and NEP proteins for nuclear export. 
 Nuclear export of vRNPs occurs after expression of late viral M1 and NEP genes and termination 
of vRNA replication.11 M1 interacts with both NEP and vRNPs. As NEP contains a nuclear export signal, it 
is able to recruit the exportin chromosome maintenance gene 1 (Crm1) and is able to undergo caspase-
dependent nucleo-cytoplasmic trafficking in the absence of M1 and NEP. The nuclear nucleotide 
exchange factor RCC1 triggers Ran-GDP to Ran-GTP exchange, which, in turn, associates with Crm1 to 
facilitate vRNP nuclear transport through the NPC. Additionally, phosphorylation of the M1, NEP, and NP 
is likely required for nuclear export.51 
 
Virion assembly and budding 
 During the assembly process, viral proteins are trafficked to the apical domain of polarized 
infected cells56 along cellular pathways to either lipid rafts (for HA and NA) or non-lipid raft domains (for 
M2).57 NP has been shown to be associated with actin microfilaments (suggesting cytoskeleton 
trafficking) and lipid rafts.57 M1 binds lipids, RNA, RNP, and NP, is associated with HA and NA tails, and 
may rely on piggybacking on other viral proteins for transportation to the apical domain. Bud initiation 
requires outward bending of the plasma membrane.18 Lipid rafts, as well as viral proteins HA, NA, M2, 
and M1, play a role in the membrane curvature and bud initiation at the budding site.18 Fusion and fission 
(a separation or splicing) are required for bud closure of new virions – fusion between the viral and 
cellular membranes and then fission of the viral bud from the cell membrane.18 The IAV viral bud pinches-
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off at the neck region, which is devoid of lipid rafts and, therefore, does not contain HA and NA or M1 on 
the outer and inner membrane leaflets, respectively (but does contain M2).11 Finally, the NA functions as 
a sialidase, releasing progeny virion from the sialic acid receptor of infected cells.58,59  
Cellular signaling pathways 
 There are several cellular pathways involved during IAV infection. The IκB kinase (IKK)/nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway has traditionally been considered 
a regulator of IAV infection due to its induction of interferon (IFN) type 1 expression (IFN-α and IFN-β).60 
In addition to IFN type-I up-regulation, however, the IKK/NF-κB pathway has also been shown to be 
required for influenza infection.61 Briefly, IKK-2 is activated by vRNA accumulation and/or expression of 
viral proteins.62 A cascade of phosphorylation events occurs where IκB-α is phosphorylated and releases 
p50/p65 NF-κB transcription factors for nuclear import and NF-κB activation.63 NF-κB activation in turn 
leads to expression of IFN-β, proapoptotic factors (e.g., TRAIL, Fas, and FasL),64 and suppressor of 
cytokine signaling (SOCS)-3.65 While IFN-β primarily functions as an innate antiviral cytokine, the 
simultaneous expression of SOCS-3 limits this response.65 Furthermore, TRAIL and FasL activate 
caspase-3 which allows release of vRNP from the nucleus due to caspase-mediated disruption of the 
NPC.66,67  
 Like the IKK/NF-κB pathway, phosphatidylinositol 3-kinase (PI3K)/Akt (a serine/threonine protein 
kinase) activation induces both antiviral and proviral responses.68,69 The pathway is activated when the 
PI3K regulatory protein p85 binds to the viral protein NS1. PI3K phosphorylates interferon regulatory 
factor (IRF)-3, stimulating IFN-β expression. PI3K also phosphorylates phosphatidylinositol-4,5-
biphosphate (PIP2), which then phosphorylates phosphatidylinositol-3,4,5-triphosphate (PIP3).70 PIP3 
then indirectly phosphorylates Akt, which activates NF-κB and inhibits proapoptotic factors such as 
caspase 3, caspase 9, and glycogen synthase kinase 3 (another serine/threonine protein kinase),69 thus, 
preventing premature cell apoptosis.  
 Finally, the Raf/mitogen-activated protein kinase kinase (MAP2K or MEK)/extracellular signal-
regulated kinase (ERK) pathway is stimulated by the clustering of HAs on lipid rafts during late infection 
and corresponds with vRNP nuclear export.71 IAV replication triggers increased diffusion of the small 
GTPase H-Ras and activation of protein kinase Cα (PKCα). Both H-Ras and PKCα activate Raf, which 
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initiates a cascade of phosphorylation events, starting with the phosphorylation of MEK.72 MEK in turn 
phosphorylates and activates ERK, which ultimately leads to cytokine up-regulation. ERK also regulates 
vRNP export via direct phosphorylation of either NP or NEP.73 
 
Host-pathogen interactions  
 Virions that are able to enter the host cell are recognized by a variety of pathogen-associated 
molecular patterns that stimulate pattern-recognition receptors to begin down-stream cell induction of 
Type I IFN, interleukins (IL), and other cytokines. Toll-like receptor-7 (TLR-7) is activated by single 
stranded RNA (ssRNA),74,75 and results in production of pro-inflammatory cytokines and chemokines, as 
well as expression of co-stimulatory molecules via activation of transcription factor NF-κB. The presence 
of ssRNA also activates retinoic acid inducible gene-1 (RIG-1),76 which contains RNA helicase-like 
domains that bind double stranded RNA (a replication intermediate) and two caspase activation and 
recruitment domains (CARDs) that interact with adaptor proteins77 (such as IFN-β promoter stimulator -1). 
Activation of CARDs up-regulates IRF-3 and IRF-7 by phosphorylation of I-κB kinase family members. 
IPS-3 activates NF-κB and Jun N-terminal kinase (JNK), which enhances binding of the ATF-2/c-jun 
transcription factor to the IFN-β promoter.78 IFN-α and -β bind to interferon receptors coupled to Janus-
family tyrosine kinase, which phosphorylates STAT proteins along the JAK-STAT pathway, activating 
transcription of oligoadenylate synthetase, PKR kinase, and the Mx gene.79 IFN-α and -β also increase 
MHC class I expression and antigen expression in cells, thus, rendering IAV-infected cells more 
susceptible to cytotoxic T cells (CTLs) and activated dendritic cells (involved in neutralization and antigen 
presentation), macrophages (involved in phagocytosis and antigen presentation), and NK cells (mediates 
antibody-dependent cell cytotoxicity).80 Interestingly, NS1 protein inhibits the activation and/or signaling of 
antiviral proteins such as RIG-I, PKR, 2’,5’ oligoadenylate synthetase, activators of mitogen-activated 
protein kinase, and Type I IFN transcription factors.79,81 
 Cellular signaling ultimately leads to activation of alveolar macrophages and dendritic cells.80 
Antigen presentation by these cells results in an adaptive immune response. There are both IAV HA-
specific82-84 and NA-specific85 antibody binding regions, which, at least in the case of HA-bound 
antibodies, results in hindering the acid pH-induced conformational change of the HA and virus 
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neutralization.84 Cellular responses include both CD4+ (T helper-1 or Th1) and CD8+ (CTL) cells. Upon 
activation, respiratory dendritic cells (rDC) migrate to lymph nodes where rDC pass on antigen to resident 
CD8α+DC and then both interact with naïve antigen-specific CD8 T cells.80 CTLs undergo activation, 
proliferation, differentiation, and, finally, migration to the site of infection, while CD8 cells undergo a 
second direct interaction with MHC I-expressing antigen presenting cells.80 Meanwhile, CD4 cells 
experience both antigen-dependent and -independent phases. During the antigen-dependent phases 
(days 0-2 of infection), naïve CD4 cells are activated by antigen presenting cells and begin secreting IL-2. 
Antigen drives further Th1 cell proliferation before eventual death of the antigen-presenting cell.86 The 
antigen-independent phase (days 2-5 of infection) involves cytokine induction (especially by IL-2) of CD4 
T cell expansion and differentiation, while activated Th1 cells differentiate into highly polarized cells.86 
 
IAV species-specificity 
 Although every gene segment has been shown to contribute to IAV species-specificity,87-91 the 
HA, which contains the receptor-binding site, has been found to be the major host range determinant 
maintaining the influenza species barrier. Matrosovich and others have published reports on the species-
specificity of the alpha-linkage between terminal SA and adjacent galactose (gal) of glycans covalently 
attached to glycoproteins or glycolipids on epithelial cells.31,32 SA receptors linked to gal by an α2,3gal 
linkage have been found to preferentially bind avian and equine IAVs, while α2,6gal linked SA receptors 
bind human IAVs.27,30-32 Naturally, it follows that the receptors expressed in respiratory epithelium 
coincide with the binding preference of host-specific IAVs. For example, the human respiratory tract 
expresses mostly α2,6gal linked SA receptors, while the avian gastrointestinal and the equine respiratory 
tracts express mostly α2,3gal linked SA receptors.9,33-37 Interestingly, lower respiratory tract tissues (i.e., 
lung) express receptors with both types of SA linkages in several species.35,Appendix A It is this mixture of SA 
receptors in the lower respiratory tract that has been postulated as the mechanism for H5N1 infection in 
humans.35 Quail and swine express both SA-α2,3-gal and SA-α2,6-gal glycans throughout their 
respiratory epithelium, and, therefore, pose as potential mixing vessels for IAVs.92,93 The biochemical 
structure of the SA (Neu5Ac or Neu5Gc acids) also contributes to species-specificity. For example, the 
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equine respiratory and duck gastrointestinal tracts consist of mostly Neu5Gc SA, while human and swine 
respiratory epithelium express mostly Neu5Ac SA.29,37,94  
 
IAV infection in dogs and CIV emergence 
 Despite occasional accounts of IAV infection in dogs,95-97 historically, dogs were not considered 
natural hosts for IAV. In past instances where dogs have been infected with EIV, there were no reports of 
sustained transmission of the virus among canine hosts.9,10,98 However, in 2004, racing greyhounds at a 
Florida track were afflicted with an IAV and appeared to be spreading the virus to other dogs at the 
facility.7 Early cases of influenza infection in these dogs resulted in ether mild clinical infections signaled 
by fever and 10-14 days of coughing (14/22 dogs) or severe hemorrhagic pneumonia and death (8/22).7 
Furthermore, it was difficult to decipher whether greyhounds were more susceptible to IAV because of 
genetic differences in the breed, immunosuppression and stress that might accompany the rigors of 
racing, or severe cytokine/chemokine induction caused by the virus itself. Chemokine storm, high viral 
load, and neutrophil migration have been associated with bronchointerstitial pneumonia in dogs 
experimentally infected with canine-adapted H3N2 IAV.99 Indeed, CIV-inoculated alveolar macrophages 
have been shown to induce tumor necrosis factor-alpha and IL-10,100 and viral antigen has been found in 
alveolar macrophages in experimentally infected dogs.101 In fatal cases of H5N1-infected humans, both 
hypercytokinemia and high viral loads were noted.102 However, regardless of the reason for severe 
clinical illness in greyhounds, the Florida IAV outbreak was the first documentation of sustained dog-to-
dog IAV transmission and established CIV as a potential threat to canine health. By April 2005, CIV had 
spread to racing tracks in Iowa, and, though the case fatality rate (<5%) was much lower than in Florida, 
the attack rate was 100%, indicating all dogs at these facilities were susceptible to CIV.103  
 Generally, the onset of CIV symptoms in dogs occurs about three days after exposure to the 
virus. Clinical signs include an elevated temperature (>103.0°F), a dry, persistent, non-productive cough, 
serous or mucopurulent discharge, as well as weight loss, anorexia, and lethargy.104 Viral shedding has 
been observed from day 2 through day 7 after exposure to the virus, with an antibody response 
detectable after day 7 (Appendix A). The timeline below (Figure 2-1) illustrates the phases of a non-




 Genetic analysis of IAVs isolated from dogs revealed close relatedness with equine influenza 
virus (EIV) H3N8 isolates from the Florida Clade 1 sublineage.8 Indeed, several studies have shown that 
EIV and CIV share the same receptor-binding preference (SA-α2,3-gal).105,Appendix A Initially, at least five 
changes from the HA EIV consensus amino acid sequence were identified for CIV,7,8 although this 
number has been expanded to 19 conserved (or consistent) amino acid substitutions among six IAV 
proteins in CIV strains isolated since 2006.106 These include a total of nine HA mutations (residues 29, 54, 
83, 118, 222, 261, 328, 479, and 483), four PB2 mutations (residues 107, 221, 292, and 374), one PB1 
mutation (residue 200), one NP mutation (residue 375), and two NA mutations (residues 62 and 147). 
Studies examining intrahost evolution of CIV in dogs pre- and post-vaccination showed that mean genetic 
diversities on the HA gene range from 0.1-0.2% in samples taken from the same individual on different 
days, suggesting high mutation rates in vaccinated dogs.107 Furthermore, isolates from dogs taken in 
humane shelters, racing tracks, and veterinary hospitals had a mean nucleotide substitution rate of 2.1 x 
10-3 per site per year for the HA gene.108 Evolution of CIV into a canine-specific lineage might perhaps 
explain the reduced replication of recent CIVs seen within the CIV-infected equine host.105,109 It is 
interesting to note that EIV is not similarly restricted in dogs, as seen recently in both experimentally and 
naturally EIV-infected dogs.98,110,Appendix A  
 Although it is clear that CIV is evolving within the canine host, the selection pressures for such 
evolution are less apparent. One major factor that might contribute to genetic selectivity is herd-immunity. 
 
 
Figure 2-1. Timeline of CIV infection in dogs. 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With the recent production of a CIV vaccine,111 as well as evidence of high CIV seroprevalences (42-97%) 
reported in shelter dogs,7,112 it is possible that mutations allowing viral immune escape are being 
positively selected. Genetic analyses of CIV isolates since 2006 have thus far found substitutions of two 
amino acid residues within HA antigenic regions.108 Clearly, more research is needed to determine CIV 
prevalence in the general dog population to accurately determine whether selection might be due to a 
large number of immuno-protected dogs or to some other factor. In addition, there is a gap in knowledge 
of how CIV is spread among dogs and between dog populations. Several studies suggest direct contact 
to be the route of transmission for CIV in dogs.113,Appendix A However, the transmission dynamics between 
dog populations is virtually unknown, as are the epidemiological and ecological factors contributing to 
infections within these populations. Finally, frequent genomic analyses are required to monitor antigenic 
drift of CIV in dogs. The studies presented hereafter attempt to address these gaps, as well as increase 
our understanding of CIV and its threat to canine health.  
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CHAPTER THREE: SENSITIVITIES OF DIAGNOSTIC TESTS FOR DETECTING CANINE INFLUENZA 
VIRUS IN NASAL SWAB SAMPLES  
 
INTRODUCTION 
Canine influenza virus (CIV) was first detected in greyhounds at a Florida racetrack in 2004 and 
has since been isolated from dogs throughout the United States.7,114 Phylogenetic analysis indicates that 
CIV is related to contemporary equine H3N8 influenza viruses (single-stranded negative-sense RNA 
viruses; family Orthomyxoviridae), though CIV is clearly evolving into its own distinct H3 lineage.8,106 
Symptoms of CIV infection include serous or mucopurulent nasal discharge, fever (>103.0°F), and a dry, 
persistent, non-productive cough, as well as weight loss, anorexia, and lethargy.104 Because these 
symptoms mirror the clinical signs of infectious tracheobronchitis (referred to as “kennel cough” or “canine 
infectious respiratory disease” [CIRD]), which can be caused by Bordetella bronchioseptica, canine 
parainfluenza virus, Mycoplasma spp., canine adenovirus-2, and/or canine distemper virus, CIV should 
be considered in the differential diagnosis for dogs with acute respiratory disease. The ability to 
differentiate severe respiratory illness caused by CIV from other pathogens associated with CIRD is 
paramount to initiation of appropriate therapeutic and biosecurity interventions and to preventing further 
transmission of CIV.  
Currently, serologic tests are a key tool in the diagnosis of canine influenza infection. As most 
serologic assays are fairly easy to perform and cost-effective and multiple samples can be collected and 
tested simultaneously, serologic testing is particularly useful for large-scale disease surveillance. While 
valuable, there are also several limitations to serologic testing. For instance, serum antibodies indicate 
exposure to the virus, but do not necessarily indicate active infection or disease. The most common 
reason for a negative result, despite clinical disease, is that insufficient time has passed between 
exposure and measurement of an antibody response. While specific influenza antibodies have been 
detected as early as seven days following experimental H3N8 influenza infection,115 serologic testing 
often provides only retrospective information. However, decisions regarding outbreak control and 
treatment must often be made before serologic testing can confirm active infection.  
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Virus isolation (VI) in embryonated chicken eggs or cell culture has traditionally been considered 
the “gold standard” in influenza diagnostics;116 however, due the fact that the procedure can be time 
consuming and cumbersome, other sensitive diagnostic methods have been developed for rapid 
influenza detection. To this end, several approaches, including reverse transcriptase (RT)-polymerase 
chain reaction (PCR) assays, enzyme-linked immunosorbent assays (ELISA), and antigen capture tests, 
are routinely performed to determine influenza infection in patients with acute respiratory illness. 
Nucleoprotein (NP) rapid influenza diagnostic tests (RIDTs) have particularly become popular in the 
hospital and field setting. These antigen-detecting tests, such as Directigen Flu A+B (BD Diagnostic 
Systems, Sparks, MD) and Flu Detect (Synbiotics, San Diego, CA), allow for rapid on-site diagnosis of 
influenza. However, low sensitivities of RIDTs for the detection of influenza virus shedding have been 
reported.117-119 Alternatively, highly sensitive quantitative or real-time RT-PCR (rRT-PCR)-based assays 
have been developed and implemented in many diagnostic laboratories for detection and quantification of 
influenza viruses.120-122 By employing a target-specific fluorescent probe, rRT-PCR-based assays 
eliminate the need to distinguish the target by PCR fragment size on electrophoresis or hybridization with 
probes after PCR. Additionally, by combining reverse transcriptase activity, a necessary first step in 
amplification of genomes of RNA viruses, and a traditional PCR reaction in one assay, the risk of cross-
contamination decreases. The advantages of rRT-PCR over other diagnostic methods include its high 
sensitivity, high specificity, and rapid turnaround time,120,121,123,124 and, as such, rRT-PCR assay meets the 
requirements for CIV detection in dogs with CIRD. Recently, members of the Landolt laboratory 
developed a one-step rRT-PCR assay method based on the amplification of the CIV matrix (M) gene for 
rapid diagnosis of influenza infection and quantification of nasal virus shedding in dogs. The objectives of 
the current studies were to (1) examine whether the rRT-PCR assay could serve as an effective method 
for influenza virus detection and quantification, and (2) evaluate the performance of the “patient side” 




MATERIAL AND METHODS 
Viruses. Viral stocks of equine influenza H3N8 strains, A/equine/KY/1/1981 (kindly provided by 
Dr. D. P. Lunn, Colorado State University) and A/equine/WI/1/2003 (kindly provided by C. W. Olsen, 
University of Wisconsin-Madison), as well as and canine H3N8 influenza clinical isolates, 
A/canine/CO/224986/2006 (GenBank HQ917678, HQ993101) and A/canine/CO/148902/2006 
(HQ917679, HQ993102), were grown in either 10-day old embryonated chicken eggs or Madin Darby 
canine kidney (MDCK) cells. 
Clinical samples. There were two separate canine populations from which clinical samples were 
collected. A total of 124 shelter and household dogs demonstrating symptoms of CIRD (e.g., tachypnea, 
cough, nasal discharge) were swabbed between March 2006 and April 2007 by clinicians at Colorado 
State University Veterinary Teaching Hospital (CSU VTH) or on-site at shelters reporting CIRD. Briefly, a 
sterile polyester-tipped swab (Dacron Polyester, Hardwood Products Company, Guilford, ME) was 
inserted into the nostril of each dog and, if possible, a second swab was collected from the pharynx of 
each animal. The swab samples were immediately placed in different vials of 1 ml viral transport medium 
(phosphate buffered saline [PBS], 5mg/ml bovine serum albumin [BSA], 2,000 U/ml potassium penicillin 
G, 4 mg/ml streptomycin, 16 µg/ml gentamicin, and 100 U/ml nystatin) and stored at -80°C. Additionally, 
two nasal swabs were collected at the same time from 1372 dogs housed in one of six different humane 
shelters participating in a large-scale CIV surveillance program, which included shelters from California, 
Colorado, Florida, New York, South Carolina, and Texas between December 2009 and November 2010. 
The first nasal swab sample was collected and processed according to the recommendation of the 
manufacturer of the Flu Detect RIDT on site at the humane shelter. The second nasal swab sample was 
collected as described above and stored at 4°C before being shipped to the laboratory overnight on ice. 
All studies were reviewed and approved for conduct by the CSU Institutional Animal Care and Use 
Committee prior to initiation. 
Virus Isolation. Influenza viruses were isolated by inoculating both MDCK cells and the allantoic 
cavity of 10-day old embryonated chicken eggs with 200 µl of thawed viral transport medium from the 
nasal and pharyngeal swab specimens collected at CSU VTH. Inoculated eggs were kept at 37°C in a 
humid incubator for 72 hours. MDCK cells were grown in 6-well cell culture plates in Eagle’s minimum 
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essential medium (MEM; Gibco/Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum 
(FBS; Gibco/Invitrogen). Before inoculation, cells were washed twice with MEM. Each plate contained a 
negative (mock-inoculated) and positive (A/canine/CO/224986/2006) control well. After inoculation, 2 ml 
of MEM supplemented with 2.25mg/ml BSA, 50 mg/ml penicillin-streptomycin, 250 µg/ml amphotericin B, 
and 1 µg/ml tolylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (Worthington 
Biochemical Corp, Lakewood, NJ) was added to each well. Inoculated cells were incubated for 48 to 72 
hours at 37°C and 5% CO2 before cell culture supernatants were harvested. Cell culture supernatants 
were passaged twice and allantoic fluid was passaged up to three times in embryonated chicken eggs. 
Immunocytochemistry using the anti-influenza A NP antibody 68D2 (kindly provided by Drs. M. McGregor 
and Y. Kawaoka, University of Wisconsin-Madison) was used to detect influenza virus infection and 
replication in the MDCK cells. Presence of influenza virus was further confirmed in both embryonated 
chicken egg- and MDCK-grown viral stocks by RT-PCR amplification (described below) and gel 
electrophoresis, using a 10% polyacrylamide gel (10% acrylamide 1 × Tris-borate-EDTA [BioRad, 
Hercules, CA] gel), of the M, hemagglutinin (HA), and neuraminidase (NA) genes. 
RT-PCR amplification and sequencing of HA and NA genes. The full-length protein coding 
regions of the HA and NA gene segments from each of the egg- and cell-isolated viruses were amplified 
by a two-step RT-PCR. Briefly, isolated viral RNA was reverse transcribed using SZAHA or SZANA 
primers125 and SuperScript™ III reverse transcriptase (Gibco/Invitrogen). HA and NA cDNAs were further 
amplified by PCR using Platinum® Taq DNA polymerase high fidelity (Gibco/Invitrogen). PCR products 
were analyzed by direct cycle sequencing (ABI Big Dye; PE Applied Biosystems, Foster City, CA) at the 
Proteomics and Metabolomics Facility at CSU (http://www.dnatools.com). Nucleotide and amino acid 
sequences were determined using DNASTAR (Lasergene 7.0, Madison, WI) software. 
Primers and probes. rRT-PCR primers and probes were designed based on influenza A virus M 
gene sequence information obtained from a GenBank BLAST search 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). To identify conserved regions in the M gene, nine 
sequences of equine and canine H3N8 influenza viruses isolated in North America since 1963 were 
aligned with ClustalW (http://www.genome.jp/tools/clustalw/). Primers and probes were selected using the 
Beacon Designer software (Premier Biosoft Inc., Palo Alto, CA). A 144-bp product from the M gene 
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between nucleotides 130 and 274 was amplified with the forward primer (5’ GAA CAC CGA TCT TGA 
GGC ACT C 3’) and reverse primer (5’ GGC ATT TTG GAC AAA GCG TCT AC 3’). The 5’ reporter dye 
(6-carboxyfluorescein [FAM]) labeled probe consisted of 23 nucleotides (5’-AGT CCT CGC TCA CTG 
GGC ACG GT-3’).  
One-step rRT-PCR assay. From each nasal and pharyngeal swab sample collected at CSU VTH 
and the six humane shelters, viral RNA was extracted from 140 µl of viral transport medium using the 
QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The 
viral nucleic acid was eluted in a final volume of 60 µl RNase-free water before storage at -80°C. The 
one-step rRT-PCR assay was performed according to the manufacturers’ recommendation with 
modifications. Briefly, a 5 µl-aliquot of RNA template was mixed with 20 µl of premixed reaction solution 
(iScript One-Step RT-PCR Kit [BioRad]) containing 200 nmol each of the forward and reverse primers, 80 
nmol of the probe, as well as all the components necessary for the RT-PCR reaction. RNA from each 
swab sample was run in duplicate. Negative controls consisted of water and neat transport medium. The 
positive control consisted of 10 TCID50 of A/canine/CO/224986/2006 (H3N8) in viral transport medium. To 
increase the throughput for sample processing, the epMotion Ep5070 (Eppendorf, Hamburg, Germany) 
automated system was used to load 96 well plates. Amplification and detection were performed using the 
Mastercycler Realplex (Eppendorf) under the following conditions: 10 min at 52°C, 5 min at 95°C, 
followed by 45 cycles of 10 sec at 95°C and 45 sec at 68.4°C. Optimization of the thermal-amplification 
profile and concentration of primers were performed using SYBER GREEN (BioRad). To confirm product 
size and PCR specificity, 25 µl of the PCR product were analyzed by gel electrophoresis, using a 10% 
polyacrylamide gel (10% acrylamide × Tris-borate-EDTA gel). Amplified products were visualized by UV 
transillumination following staining with 0.5 µg/ml ethidium bromide. 
RNA synthesis by in vitro transcription. Purified full-length M gene RNA was used as the 
standard for calibration of influenza virus M gene copy number, which was in vitro transcribed from the 
corresponding full-length M gene template of A/equine/WI/1/2003 (which is homologous with the CIV M 
gene) cloned into a plasmid vector (pGEM-T Easy vector [Promega, Madison, WI]). The directionality of 
the insert was confirmed by direct cycle sequencing using T7 primers. M gene RNA was transcribed with 
the RiboMAX Large Scale RNA production systems kit (Promega) from the T7 promoter according to the 
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manufacturer’s instructions, treated with RNase-free DNase I, suspended in RNase-free water, quantified 
by spectrophotometer, and stored at -80°C at a concentration of 0.12 ng/µl.  
rRT-PCR standardization and determination of detection limits. The rRT-PCR assay was 
standardized using dilution series of four H3N8 isolates grown in MDCK cultures (A/equine/ KY/1/1981, 
A/equine/WI/1/2003, A/canine/CO/224986/2006, and A/canine/CO/148902/2006) ranging from 104 to 10-6 
TCID50/ml in viral transport medium and from nasal swab samples obtained from dogs showing no clinical 
signs of CIRD. To determine the minimum detection level of virus RNA by rRT-PCR, the in vitro 
transcribed RNA was serially diluted in RNase-free water to produce dilutions ranging from 107 to 100 
genomic equivalents/µl of viral M gene RNA. A cycle threshold (Ct) cut-off value for the rRT-PCR assay 
was determined by a parametric receiver operating characteristic (ROC) curve analysis, using the raw Ct 
values of the nasal and pharyngeal swab samples. To account for assay variation, the median Ct values 
of over 50 RNA standard curves, run on different days, were determined.  
Rapid influenza diagnostic tests. Two different RIDTs were used in these studies. Directigen 
Flu A +B (herein referred to as DFA; BD Diagnostic Systems, Sparks, MD), an enzyme immunoassay 
test, was performed on every nasal and pharyngeal swab that was also assayed by rRT-PCR from dogs 
sampled by a CSU VTH veterinarian. Briefly, 125 µL of viral transport medium containing the swab 
sample was added to the DFA test membrane. Influenza A virus NP antigen that bound to the membrane 
was subsequently detected using an enzyme-conjugated anti-NP monoclonal antibody. Each swab 
sample was evaluated and scored as positive (characterized by the development of a purple triangle) or 
negative. The second RIDT, Flu Detect (herein referred to as FD; Synbiotics, San Diego, CA), a lateral 
flow avian influenza A antigen test kit, also detects the NP antigen. To determine efficacy of the FD test, 
humane shelter personnel collected nasal swab samples from incoming dogs and immediately performed 
the FD test on-site. Briefly, the nasal swab was placed into a tube containing extraction buffer before 
rotating the swab 5-10 times. The swab was then pressed up against the sides of the tube to remove any 
remaining liquid. A test strip was submerged into the tube and allowed to incubate for 15 min at room 
temperature before being read as either positive (two pink/purple bands – the test line and control line) or 
negative (one pink/purple band – the control line only). All reagents, tubes, and swabs were provided with 
the test kit. For consistency, only one or two people from each shelter conducted all of the FD tests.  
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Statistical analyses. To determine significance between standardized Ct values among samples 
and between shelter and household dog populations, Student t-tests were calculated using GraphPad 
Prism version 5 for Mac OS X (GraphPad Software, La Jolla, CA). Diagnostic test sensitivity and 
specificity estimates were determined by the stochastic latent class analysis modeling approach 
described by Branscum et al.126 using Gibbs sampling.127 The dataset was divided into two populations 
based on whether the dog sampled at CSU VTH resided in a shelter (n=97) or household (n=27), as 
these two dog populations have been shown to have different seroprevalence rates of CIV.7,112,128 
Independence and dependence is determined by the type of biological sample tested.126 Therefore, three 
models were used to evaluate detection of CIV in the samples obtained from CSU VTH: two conditional 
independent tests in two populations comparing VI to DFA and VI to rRT-PCR (VI is a measure of 
infectivity and replication, while DFA and rRT-PCR specifically detect genes or gene products), two 
conditional dependent tests in two populations comparing DFA to rRT-PCR, and three tests (two 
dependent [DFA, rRT-PCR], one independent [VI]) in two populations. “Conditional” refers to the tests 
being conditional on the infection status of the individuals sampled. As both the rRT-PCR and DFA test 
results were separately compared to VI in the two conditional independent tests assimilations, a total of 
four models were analyzed. Table 3-1 describes the sensitivity and specificity prior probability 
distributions for the three diagnostic tests evaluated. The priors for CIV prevalence were based on 
previous studies7,112,128 to a mode of 0.04 and 0.40 for household and shelter dogs, respectively, both with 
a 95th percentile of 0.7. Inferences were based on 100,000 iterations (with a burn-in of 5,000 iterations) 
after six chains indicated no lack of convergence. All models were run with WinBUGS 1.4.3 freeware.129 
Table 3-1. Estimates, modes, 95% probability intervals, and beta distributions used as the prior 
distributions in the stochastic latent class models. 
 Estimate Mode 95% Probability Interval Beta distribution 
Viral isolation sensitivity >0.5 0.90 0.436 0.982 a=5.3842 b=1.4871 
Viral isolation specificity >0.5 1.00 0.426 0.994 a=4.3219 b=1.0000 
Directigen sensitivity >0.5 0.70 0.464 0.861 a=13.3221 b=6.2809 
Directigen specificity >0.5 0.90 0.436 0.982 a=5.3842 b=1.4871 
rRT-PCR sensitivity >0.5 0.90 0.436 0.982 a=5.3842 b=1.4871 
rRT-PCR specificity >0.5 0.90 0.436 0.982 a=5.3842 b=1.4871 
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As there was only one population (shelter dogs) sampled for the RIDT FD analysis, sensitivity, specificity, 
positive predictive value, and negative predictive value were determined using traditional calculations 
from a 2 x 2 contingency table.  
 
RESULTS 
 Development of rRT-PCR and sample analysis. The minimum detection level of influenza virus 
M gene RNA was determined to be 1000 copies per 
reaction, or a Ct value of 34, by rRT-PCR. Negative 
samples were considered to have Ct values above 34 up 
to 40 (which was considered undetectable). Amplification 
of dilutions of the M gene RNA transcripts showed linearity 
over a range of eight orders of magnitude, from 100 
through 107 (Table 3-2). For the RNAs from the H3N8 
influenza strains serially diluted from 104 to 10-6 TCID50/ml, 
the minimal levels of detection for the isolates were as follows: A/canine/CO/224986/2006, 1 TCID50; 
A/canine/CO/148902/2006, 1 TCID50; A/equine/KY/1/1981, 10 TCID50; and A/equine/WI/1/2003, 10 
TCID50. The threshold of the rRT-PCR assay on the basis of the mid-point of the linear region of the 
amplicon development curve was defined as Rn=0.1. Assay variability was calculated based on the Ct 
values. Coefficients of variation were between 1.5 and 4.7% for the Ct values and were comparable to 
those from previously published rRT-PCR studies.120 Of the total 122 swab samples tested for influenza 
by rRT-PCR, the overall Ct mean difference between positive (Ct of 34 and under) and negative 
(Ct over 34) samples was statistically significant (P<0.0001; t=12.25 df=120), with a mean Ct value of 
29.6 (±0.7) (median 32.0) for positive swabs and 36.9 (±0.2) (median 36.0) for negative swabs (Figure 3-
1a). The negative and positive results from the 83 samples that were inoculated into eggs or MDCK cells 
for VI and the 119 samples tested by DFA were significantly different as well (PVI<0.0001, tVI=7.538 
dfVI=81; PDFA<0.0001, tDFA=11.97 dfDFA=117), although there was no difference between the VI and DFA 
positive shelter and household dog samples (P=0.49, t=0.6899, df=120) (Figure 3-1b). The Ct values of 
positive VI and DFA ranged from 18 to 33 and from 18 to 36, respectively. Among the 13 dogs with both  
Table 3-2. Median cycle threshold values 




Median cycle threshold 
value (±SEM) 
<101 >38.1 or undetectable 
102 37.2 (0.15) 
103 34.5 (0.20) 
104 31.1 (0.24) 
105 27.0 (0.19) 
106 24.1 (0.16) 
107 20.2 (0.16) 
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nasal and pharyngeal swab samples available for 
testing, seven dogs had positive nasal swabs on 
rRT-PCR (Ctmean=29.1 ±1.7; median 29.0), but 
only four out of those seven animals also had a 
positive pharyngeal swab (Ctmean=31.0 ±1.4; 
median 32.0). The difference in Ct values between 
the 13 paired nasal and pharyngeal swab samples 
(Figure 3-1c) was not statistically significant 
(P=0.06; t=2.076 df=12).  
VI from nasal and pharyngeal swabs. 
Influenza virus was isolated in 34.1% (15/44) of 
the 10-day old embryonated chicken eggs and 
7.1% (5/70) of the MDCK cell cultures inoculated 
with nasal and pharyngeal secretions. In total, 16 
influenza viruses were isolated. There was 
agreement between 21 of the 31 (67.7%) swabs 
that were inoculated into both eggs and cell 
culture, with 4 positives and 17 negatives. 
Interestingly, there were 11 viruses isolated in 
eggs, but not in MDCK cells. Conversely, there 
was one isolate that replicated in MDCK cells only. 
Four viruses replicated in both. All CIV isolates fell 
into the canine H3N8 sub-lineage differing from 
EIV H3N8 at the five HA amino acid residues 
previously described for CIV (N54K, N83S, 








Figure 3-1. Comparison of cycle threshold values 
for (a) all nasal and pharyngeal swabs collected 
from dogs with canine infectious respiratory 
disease, (b) shelter and household dog samples 
testing positive and negative on virus isolation 
(VI) and/or Directigen (DFA), and (c) paired nasal 
and pharyngeal swabs from dogs with canine 
infectious respiratory disease. The bottom and 
top of the box represent the 25th and 75th 
percentiles, the horizontal bands are the 
medians, and the whiskers depict the maximums 
and minimums. 
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 Comparison of VI, DFA, and rRT-PCR in detecting CIV. The three tests had varying 
sensitivities for detecting CIV from the swab 
samples collected (Table 3-3). While 19 (16.0%) of 
the 119 total nasal and pharyngeal swab samples 
tested by DFA were positive, only 10 of those 
were also positive by VI. In total, VI and DFA 
agreed on 68 of 81 (84.0%) samples. Using a Ct 
cut-off of 34, of the 83 swab samples tested by 
both rRT-PCR and VI, 16 (19.3%) were positive by 
both assays and 38 (45.8%) were negative by 
both assays. There were 29 (34.9%) samples that 
were positive by rRT-PCR, but virus was not isolated in either eggs or cell culture. Surprisingly, the 
percentages of positives, although different among the tests performed, were consistently higher for 
household dogs compared to the shelter dogs sampled (Table 3-4). 
 
Sensitivities of VI, DFA, and rRT-PCR assays. Three stochastic latent class models were used 
to estimate the diagnostic sensitivities and specificities of VI, DFA, and rRT-PCR in detecting CIV in dogs. 
However, as these studies concentrated on the ability of the various tests to detect positivity in swab 
samples and no known true negative samples were collected, only the sensitivities of the three tests are 
reported here (Table 3-5). These sensitivities have wide ranges among the three tests and among the 
models used. The model comparing all three three-tests in two different populations, the most appropriate 
model for these data, shows DFA to have a median sensitivity of 0.65, while VI median sensitivity was a 
little higher at 0.72. In this model, the rRT-PCR assay had the highest sensitivity at 0.95. The other 
models, with the one-on-one test assessments, showed similar results.  
Table 3-4. Comparison of CIV detection by virus isolation (VI), Directigen (DFA), and rRT-PCR from 
nasal and pharyngeal swabs from shelter (s) and household (h) CIRD dogs. 
 VI (s=61, h=24) DFA (s=95, h=24) rRT-PCR (s=95, h=27) 
Swab samples Positive Negative Positive Negative Positive Negative 
Shelter 16.4% 83.6% 13.7% 86.3% 33.7% 66.3% 
Household 25.0% 75.0% 25.0% 75.0% 59.3% 40.7% 
Total 18.8% 81.2% 16.0% 84.0% 39.3% 60.7% 
 
Table 3-3. Comparison of CIV detection by virus 
isolation (VI), Directigen (DFA), and rRT-PCR 
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Evaluation of FD in detecting CIV. Of the 1372 shelter dog nasal swab samples for evaluation 
of the FD test compared to rRT-PCR, only 3 of the 38 tests that were positive by rRT-PCR were also 
positive by FD, while FD did not detect influenza virus in 35 nasal swab samples that were positive by 
rRT-PCR. Conversely, the FD test was positive for 218 of the 1334 samples that were negative by rRT-
PCR. Using traditional calculations for a 2 x 2 contingency table with rRT-PCT as the gold standard, the 
FD had a sensitivity of 7.9% (3/38), specificity of 83.7% (1116/1334), positive predictive value of 1.4% 
(3/221), and negative predictive value of 97.0% (1116/1151). The three nasal swabs positive by both FD 
and rRT-PCR had Ct values ranging from 26 to 33. Nasal swabs with negative FD results included 
samples that had rRT-PCR Ct values as low as 26. All six shelters included in the study showed similar 
inconsistencies between the rRT-PCR and FD test results. 
 
DISCUSSION 
These studies are the first to describe the development of an rRT-PCR-based assay that can be 
used specifically for detecting CIV in canine nasal and pharyngeal swabs and that evaluate common 
diagnostic methods for detecting CIV shedding in both CIRD and healthy dogs. As CIV can cause 
subclinical infection, it is imperative for disease control to correctly diagnose CIV in sick dogs that reside 
in humane shelters, are boarded, or attend canine day care.128 It is also well known that dogs shed 
influenza virus several days before any noticeable illness. Therefore, the relatively short window of 
opportunity to identify CIV-infected dogs necessitates the rapid diagnosis of CIV, even before CIRD is 
observed, to prevent any further CIV transmission.  
The finding that there is no overall statistical difference in the rRT-PCR Ct values among paired 
nasal and pharyngeal swabs samples (Figure 3-1c) suggests that collection from nasal mucosa, a less 
Table 3-5. Median sensitivity estimates and 95% probability intervals (PI) determined by stochastic latent 
class analyses 
 VI DFA rRT-PCR 
Test comparison model Estimate 95% PI Estimate 95% PI Estimate 95% PI 
Three tests 0.72 0.47, 0.96 0.65 0.48, 0.80 0.95 0.83-0.99 
Two tests (VI, DFA) 0.80 0.52, 0.98 0.696 0.52, 0.85 -- -- 
Two tests (VI, rRT-PCR) 0.64 0.37, 0.95 -- -- 0.947 0.81, 0.99 
Two tests (DFA, rRT-PCR) -- -- 0.57 0.39, 0.79 0.93 0.75, 0.99 
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invasive procedure than swabbing the pharynx, is sufficient for diagnosing influenza infection in dogs. 
Furthermore, as there were several negative pharyngeal samples that did not correspond to respective 
paired positive nasal swab samples, the nares appear to be the better site to swab when suspecting 
influenza infection. However, sampling protocols should be specific as to how deep within the nasal cavity 
a swab needs to be inserted to get an optimal mucosal sample. Canine nasal anatomy might pose a 
problem for the inexperienced as well, as the swab needs to clearly bypass the alar cartilage at the nostril 
entrance to reach the mucosa deep within the canal.  
From properly collected swabs, the rRT-PCR assay is highly sensitive in detecting CIV. The 
three-test model showed 96% sensitivity for rRT-PCR, which was much higher compared to traditional VI 
(72%) and the patient-side RIDT DFA (65%). There are several assumptions for the stochastic latent 
class analysis that should be addressed, however. The first two, (1) there were two dependent tests and 
one independent test and (2) there were two different populations, were met. DFA and PCR both detect 
the same biological phenomenon (gene or gene products), while VI relies on the presence of infectious 
virus and ability of the virus to infect and replicate in eggs or cell culture. Although the goal of humane 
shelters is to adopt dogs from the facility out into the community, there is a clear environmental difference 
between dogs residing in households versus dogs that are located within humane shelters, where they 
often co-mingle and are co-housed with other dogs. Additionally, the constant introduction of new dogs 
(often not quarantined for a sufficient period to allow for cessation of viral shedding) poses a much higher 
threat to dogs in shelters compared to dogs that live in one-dog households or that share the same space 
with familiar dogs. Thus, treating shelter and household dogs as two different populations in our 
stochastic models is valid. Indeed, seroprevalence studies conducted in shelters reporting CIRD,7,112 
show much higher seropositivity compared to the few studies done in dogs residing in homes.128,130 The 
third, and final, assumption is that there is constant sensitivity and specificity of the tests. As there is no 
indication that any of the three tests is more or less sensitive or specific for the populations sampled in 
these studies, this assumption has been met as well. 
The high sensitivity of rRT-PCR is not surprising. Other rRT-PCR assays used in influenza virus 
detection show similar sensitivities.120,123 As virus isolation has traditionally been considered the gold 
standard in influenza virus diagnostics, the discrepancies between isolating virus in embryonated chicken 
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eggs or cell culture and detecting CIV on rRT-PCR cannot be simply dismissed. In this study, virus 
isolation was carried out on samples that were frozen within 12 hours of collection and had subsequently 
been thawed. This single freeze-thaw may have resulted in a reduction of infectious virus titer and, thus, 
reduction in the sensitivity of virus detection by isolation in cell culture compared to antigen detection by 
DFA (generally performed as soon as the sample was delivered to the laboratory) and by rRT-PCR. It is 
also interesting that egg culture was more successful in isolating canine influenza viruses than was 
MDCK cell cultures. VI from embryonated chicken eggs is still considered the gold standard for equine 
influenza virus (CIV’s nearest ancestor) diagnosis.116 Accordingly, avian, equine, and canine influenzas 
have all been shown to preferentially bind receptors with glycans having sialic acid linked to galactose by 
an α2,3 linkage.28,32,105 Moreover, laboratory experience suggests that growing CIV in embryonated 
chicken eggs is not always foolproof. Indeed, a recent EIV and CIV molecular evolution study found that 
neither embryonated chicken eggs nor MDCK cell cultures were better able than the other to grow CIV.106 
What this means for CIV diagnosis is still unknown. Clearly, however, VI in eggs or MDCK cells cannot 
solely be relied upon to determine CIV infection. Therefore, as RT-PCR has been shown to be able to 
detect influenza viruses even in samples repeatedly frozen and thawed,117 the relatively high sensitivity of 
rRT-PCR and its rapid turn-around makes it the ideal test for first-step CIV analysis. VI would be the next 
logical step for sequencing and genetic characterization of positive rRT-PCR samples.  
Rapid influenza diagnostic tests might also be considered as bedside or on-site tests for CIV if 
rRT-PCR or VI is not available due to financial, geographical, or time restraints. However, the limitations 
of these RIDTs need to be understood by the user. Although the DFA was clearly better than the FD test 
at diagnosing influenza in dogs, the 95% PI for DFA sensitivity ranged from 48% to 80%, suggesting true 
positive samples in our studies might have been misdiagnosed as negative. Similarly, the FD test is very 
poor for CIV diagnosis, and, in fact, was more likely to give a false positive rather than a true positive 
result. It should be noted, however, that PPV is generally low when there is low prevalence of disease. As 
the true prevalence of CIV is currently unknown in all dog populations, it is difficult to accurately assess 
PPV, and the estimated 1.4% from the 2 x 2 calculations might actually be higher (or lower). Despite this, 
however, a practical approach for a humane shelter or a geographically remote clinic might be proper 
isolation and quarantine measures for every dog entering the facility if none of the CIV diagnostic tests 
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can be performed. Undoubtedly, there is still a need for the development of a fairly cost-effective, highly 
sensitive RIDT. 
In conclusion, the findings in these studies suggest that rRT-PCR has the highest sensitivity of 
the three methods evaluated for detecting CIV nasal shedding and can be used as a rapid diagnostic test 
for CIV. As the cost for rRT-PCR might be more than several RIDTs, facilities with financial constraints 
might want to consider testing in series, starting with a RIDT performed on-site. Any samples positive by 
a RIDT could then be sent to a veterinary diagnostic center for confirmation by rRT-PCR, while the 
potentially infected dog is isolated to minimize CIV transmission to naïve dogs. As turn-around time for 
rRT-PCR is ~1day, the quarantine period might be as short as 48 hrs, if the test is negative, or as long as 
seven days to account for viral shedding, if the test is positive. Overall, however, rRT-PCR is a practical, 
relatively inexpensive, and quick test that can be used in CIV diagnosis.  
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CHAPTER FOUR: SEROPREVALENCE AND RISK FACTORS FOR CANINE H3N8 INFLUENZA 
VIRUS EXPOSURE IN HOUSEHOLD DOGS IN COLORADO* 
 
INTRODUCTION 
 Influenza A viruses infect a wide range of species, including humans, horses, pigs, sea mammals 
and birds.1 Historically, dogs were not considered to be natural hosts for influenza. However, in 2004, an 
outbreak of respiratory disease in racing greyhounds at a track in Florida provided evidence of 
transmission of an influenza virus closely related to the contemporary equine H3N8 “Florida” lineage.7 
Over the course of that same year, outbreaks of canine influenza occurred at 14 greyhound racetracks in 
six states, and by 2005 the virus had spilled over into the non-greyhound dog population.7,8 To date, 
canine influenza virus (CIV) infections have been detected in at least 27 States and the District of 
Columbia.114 Because the virus represents a novel pathogen, all dogs irrespective of age, breed, and sex 
are potentially susceptible to infection with CIV. The virus is shed in respiratory secretions and 
transmitted in aerosols created by coughing and sneezing. As a consequence, close contact and closed 
environments appear to favor virus transmission among susceptible animals.8,104 
 While it is impossible to determine the total number of CIV infections that have occurred since 
first identification of the virus, a recent one-year study performed in our laboratory demonstrated that CIV 
was found in five of five Colorado humane shelters that experienced outbreaks of canine respiratory 
disease.131 These results suggest that CIV is a frequently detected pathogen in Colorado humane 
shelters that have a history of canine respiratory disease. To date, only a few studies have investigated 
CIV seroprevalence in non-shelter dog populations132-134 and no information is available on the 
prevalence of CIV infection in the household dog population of Colorado. To better understand the extent 
of CIV infection in household dogs in a state with a presumed high incidence of CIV infection,114 we 
sought to estimate the rates of CIV seropositivity among dogs from non-shelter environments that were 
                                                        
* This chapter was published as a brief communication in the Journal of Veterinary Internal Medicine: 
Barrell EA, Pecoraro HL, Torres-Henderson C, Morley PS, Lunn KF, Landolt GA. (2010) JVIM 24:1524-
1527. Barrell and Pecoraro contributed equally to the paper and are co-first authors. 
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seen at Colorado State University’s Veterinary Medical Center (CSU VTH). In addition, as identification of 
factors that increase the risk of CIV infection would provide a factual foundation on which to base disease 
prevention and control measures, a second objective of this study was to investigate risk factors for CIV 
infection in Colorado household dogs. 
 
MATERIALS AND METHODS 
 Study population. For this study, we utilized a prospective convenience sampling method in 
which eligible households were defined as a domestic unit located in the state of Colorado consisting of 
the members (or a member) of a family who live together along with a dog (or dogs) of undefined age, 
breed, vaccination status, or sex. While dogs that qualified under this definition were eligible for inclusion 
regardless of the reason for presentation, they were excluded from the study if their owner declined to 
provide consent. In addition, dogs were excluded if the clinician determined that blood collection would 
have caused undue stress to the animal or if the dog had received CIV vaccination. Based on the results 
of a serological surveillance study for swine influenza virus infections among unvaccinated pigs in the 
north-central United states,135 the sample size was calculated using an estimated seroprevalence of 20%. 
Prior to initiation, this study was reviewed and approved for conduct by the Colorado State University 
Institutional Animal Care and Use Committee. 
 Animals. Serum samples were collected from three different household dog populations 
presented to the CSU VTH. Over a collection period of 9 months (March to December 2009), 140 serum 
samples were obtained from household dogs admitted to the Community Practice service at the CSU 
VTH. These dogs were generally in good health and were presented for reasons such as wellness 
examinations, preventive health care, dentistry, and heartworm testing. In addition, serum samples were 
obtained from 110 dogs that had been submitted by CSU VTH clinicians to the Clinical Pathology 
laboratory from dogs of various ages, breeds, and clinical histories. The blood samples were submitted as 
part of the diagnostic investigation of a range of clinical conditions. Lastly, 75 serum samples collected 
prior to 2004 from Colorado household dogs of all ages obtained from a serum bank maintained at the 
Animal Cancer Center at CSU VTH (kindly provided by Dr. S. Lana, Animal Cancer Center, CSU) were 
used for the estimation of the pre-2004 CIV seroprevalence. 
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 Data collection. A questionnaire was administered to the 140 dog owners that presented their 
animals to the Community Practice service at CSU VTH at the time of sample collection. The 
questionnaire included the dog’s signalment (age, breed, sex), vaccination status, and past and current 
medical histories. In addition, the questionnaire addressed the length of ownership of the dog, the number 
of other dogs living in the same household, the dog’s travel history, and information about social 
interactions with non-household dogs, such as visits and/or stays at dog parks (including the number of 
visits), day-care facilities (including frequency of stays), and boarding facilities (including number and 
length of stays). 
 Serology. The levels of hemagglutination inhibiting antibodies in serum samples were 
determined by HI assays that were performed as previously described135,136 and in accordance with 
procedures recommended by the World Organization for Animal Health (OIE). Briefly, sera were 
incubated overnight at 37ºC with four volumes of receptor destroying enzyme (RDE; Denka Seiken Co, 
Tokyo, Japan) prepared from Vibrio cholera. After inactivation of the RDE enzyme by incubation of the 
samples at 56°C for 60 min, twofold serial dilutions of sera were mixed with four hemagglutinin units of 
CIV in 96-well microtiter plates. The assays were developed by adding 0.5% (vol/vol) chicken red blood 
cells (cRBCs), and the HI antibody titers were defined as the reciprocal of the highest dilution causing 
complete inhibition of agglutination. To account for potential antigenic drift the following CIV strains were 
used as antigens: A/canine/Florida/43/04 (H3N8) (kindly provided by Dr. P.C. Crawford, University of 
Florida), A/canine/CO-1/224986/06 (H3N8), and A/canine/CO-5/234550/09 (H3N8). Each sample was run 
in duplicate and each assay included both positive (positive control canine serum) and negative 
(physiological saline only) controls. Seropositivity was defined at a HI titer >1:8. 
 Statistical Analyses. Data from the questionnaires were collated with patient signalment 
information and results of serological testing. These data were validated and entered in a computer 
spreadsheet and data were summarized using contingency tables. ‘Plus four’ confidence intervals were 
calculated for the proportions of seropositive dogs by adding two successes to the seropositivity outcome 
and four to our sample size for computation of a more appropriate 95% confidence interval.137 
Associations between seropositivity and potential risk factors such as age (≥ 2 years [immature], < 2 
years [mature]), sex (male, female), history of cough in the past 6 months (yes, no), other dogs living in 
31 
the same household (yes, no), dog acquired from shelter or rescue (yes, no), dog attended day care in 
the past 6 months prior to sample collection (yes, no), dog was boarded in the past 6 months prior to 
sample collection (yes, no), dog greeted other non-household dog in the past 6 months (yes, no), and dog 
visited dog park in the past 6 months prior to sample collection (yes, no), were investigated using the 
Fisher’s Exact Test with a critical alpha of 0.05. 
 
RESULTS 
 CIV H3N8 seroprevalence. A total of 325 canine serum samples were tested. All dogs included 
in the study lived in the state of Colorado at the time of sample collection. One-hundred and forty serum 
samples were collected from dogs seen at the Community Practice service at CSU VTH between March 
and December 2009 (mean age 4.8 yrs [range 6 months - 15 years]; 73 males, 67 females). One-hundred 
and 10 samples were obtained through the Clinical Pathology laboratory from dogs that were seen by 
other clinical services at CSU VTH for various reasons between March and December 2009 (mean age 8 
yrs [range 3 months – 16 years]; 51 males, 59 females). Lastly, 75 serum samples that had been 
collected prior to 2004 were obtained. Of all serum samples collected from patients in 2009, 3.6% (9/250; 
95% CI = 1.1%, 6.1%) were antibody positive, including 2.9% (4/140; 95% CI = 0.01%, 6.1%) of dogs 
seen by the Community Practice service and 4.5% (5/110; 95% CI = 0.1%, 9.0%) of dogs seen by other 
services at CSU VTH. This difference in seroprevalence between patient groups was not statistically 
significant (P=0.48). All serum samples collected from dogs prior to 2004 were seronegative. The 
antibody titers to A/canine/Florida/43/04 were similar to those for the 2006 and 2009 isolates. The mean 
geometric log base 2 HI antibody titer for the positive serum samples was 7.5 (1:176), ranging from 5.8 to 
8.4 (1:58 to 1:341). These patterns of inhibition demonstrated the antigenic similarly between the CIV 
isolates tested and indicate that measurable antigenic drift has not yet occurred. 
 Risk factor analysis. One hundred and forty questionnaires were completed by owners 
presenting their dogs to the Community Practice service at CSU VTH. The only factor statistically 
associated with CIV H3N8 seropositivity was attendance at canine day-care within the last 6 months 
(OR=53.8; 95% CI = 6.2, 463.6; P <0.001) (Table 4-1). Additionally, although not statistically significant, 
dogs boarded in kennels within 6 months prior to serum sample collection appeared to be predisposed to 
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CIV infection (OR=8.5; 95% CI=1.4, 53.0; P=0.06). No other factors related to the dog’s signalment (age, 
breed, sex), vaccination status, medical and travel histories, or other social interactions with non-
household dogs, such as at dog park visits, were associated with CIV seropositivity. 
 
DISCUSSION 
 Findings of the present study suggest that CIV H3N8 seroprevalence in household dogs in 
Colorado is lower compared to CIV seroprevalence in humane shelters,7,112 although CIV seroprevalence 
has increased since 2004. Despite the fact that the total number of canine influenza infections that have 
Table 4-1. Results of analyses of various potential risk factors for association with CIV seropositivity 
among dogs presented to the Community Practice service at Colorado State University Veterinary 
Medical Center. 
Variable Categories No of CIV 
positive 
dogs 
No of CIV 
negative 
dogs 
OR* 95% CI** P value 
Age of dog 
 ≥ 2 years 4 85 5.4 1.1-26.6 0.16 
 < 2 years 0 51 Reference   
Sex 
 Female 2 65 1.1 0.8-1.6 0.66 
 Male 2 71 Reference   
History of cough in past 6 months prior to sample collection 
 Yes 0 18 0.7 0.1-3.6 1.00 
 No 4 118 Reference   
Other dogs living in the same household 
 Yes 3 82 1.5 1.5-1.6 0.49 
 No 1 54 Reference   
Dog acquired from shelter or rescue 
 Yes 2 40 2.4 1.7-3.4 0.35 
 No 2 96 Reference   
Dog attended day care in the past 6 months prior to sample collection 
 Yes 2 2 53.8 37.2-77.8 <0.001 
 No 2 134 Reference   
Dog boarded in the past 6 months prior to sample collection 
 Yes 2 14 8.5 6.5-10.9 0.06 
 No 2 122 Reference   
Dog has greeted other non-household dog in the past 6 months 
 Yes 4 111 2.1 0.4-10.3 0.45 
 No 0 25 Reference   
Dog visited dog park in the past 6 months prior to sample collection 
 Yes 0 26 0.5 0.1-2.3 1.00 
 No 4 110 Reference   
OR = Odds ratio, CI = Confidence interval 
* OR adjusted for zero values = [(A+0.5)×(D+0.5)]/[(B+0.5)×(C+0.5)]  
** 95% CI adjusted for zero values = exp(In(OR) +/- 1.96 x 
ln[(1/[A+0.5])+(1/[B+0.5])+(1/[C+0.5])+(1/[D+0.5])]0.5) 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occurred since first identification of CIV is unknown, a recent one-year study conducted by our laboratory 
found that five of five Colorado humane shelters that experienced outbreaks of canine respiratory disease 
(“kennel cough”) housed at least one CIV real-time PCR positive dog.131 Similarly, an earlier study found a 
97% CIV seroprevalence in shelter dogs in Florida and in dogs housed at veterinary clinics in Florida and 
New York that had a recent history of a respiratory disease outbreak.7 Taken together, these data 
suggest that CIV plays an important role in dogs with clinical respiratory disease that are housed in 
closed environments in Colorado, Florida, and New York. 
 Given the presumed high prevalence of CIV exposure in Colorado shelter dogs, it was surprising 
that the seroprevalence found in Colorado pet dogs was so low. As the canine sera demonstrated similar 
titers to canine influenza viruses isolated in 2004, 2006, and 2009, indicating a lack of measurable 
antigenic drift, the small number of seropositive dogs found in our study cannot be explained by a change 
in antigenicity of the virus. While other studies conducted in non-shelter dogs have demonstrated similarly 
low seroprevalences (0.4% and 1.2%),132,134 these studies were conducted in geographic areas where 
CIV prevalence is thought to be low (Ontario, Canada; Iowa).114 Considering the frequent detection of CIV 
in Colorado humane shelters, a potential explanation for the assumed discrepancy in the frequencies of 
CIV exposure is that influenza virus ecology is different in shelter dogs than in household dogs and 
spillover of virus from the shelter environment may not pose a common risk for most household pets 
presented to the CSU VTH. 
 Another possible reason for the low number of CIV H3N8 positive dogs found in this study is that 
the current study was a population prevalence study and not a study focusing on animals with clinical 
signs of respiratory disease. Despite this, the low seroprevalence in this study suggests that canine 
influenza virus is not a common respiratory pathogen encountered by the majority of pet dogs in 
Colorado. This notion seems to be further supported by the finding that a history of coughing within 6 
months prior to sample collection was not statistically associated with CIV seropositivity. In contrast, our 
study identified attendance at canine day-care as a risk factor for CIV exposure, supporting the notion 
that commingling of animals in closed environments favors virus transmission. This result may be used to 
target preventive strategies (e.g., vaccination) at dogs that have the greatest risk of CIV exposure, such 
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as dogs attending day-care or dogs that are being boarded. However, controlled field trials are needed to 
evaluate the value of such preventative measures in these groups of animals. 
 We recognize several limitations of this study. First, as the number of seropositive animals was 
small, the power to define risk factors for CIV exposure is low and, therefore, the data should be weighed 
carefully. Moreover, the small number of positive serum samples does increase the potential for Type II 
statistical error (not finding a statistical difference when one truly exists). As a result, it is possible that, 
although no significance was found between CIV seropositivity and other risk factors analyzed in our 
questionnaire, there may actually have been associations present. Secondly, a potential bias relating to 
the sample population also has to be considered. This study involved dogs presented to a primary 
(Community Practice Service at CSU VTH) and secondary (other veterinary services at CSU VTH) 
veterinary care facilities. This population is likely biased as there is an expected subset of animals that 
are rarely or never presented for veterinary care. As the majority of dogs included in this study originated 
from a limited geographical area, one cannot draw conclusions as to the true CIV H3N8 seroprevalence 
in pet dogs in the state of Colorado. Lastly, while published data report detection of antibodies in banked 
dog sera more than five years after collection,138 the duration of persistence of CIV antibodies in individual 
animals has not been well defined. It is possible that some of the dogs tested in this study had previously 
been infected but no longer had detectable antibody titers, which may have resulted in an 
underestimation of CIV seroprevalence in this study. Nevertheless, while it remains to be determined how 
long CIV antibodies persist in canine serum, the discrepancy between the frequent detection of CIV in 
Colorado shelters and the low seroprevalence in household dogs merits further investigation. 
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CHAPTER FIVE: SEROPREVALENCE OF CANINE INFLUENZA VIRUS H3N8 IN IDITAROD RACING 
SLED DOGS * 
 
INTRODUCTION 
 Influenza A viruses infect many different species, including various birds and mammals. 
Historically, dogs were not considered natural hosts for influenza, despite limited cases of infection.9,95 In 
2004, however, influenza virus (H3N8) was isolated from racing greyhounds at a Florida racetrack and 
the virus subsequently spread to 14 racetracks located throughout 6 states.7 By 2005, CIV was detected 
in pet and shelter dog populations as was evidenced by a study that reported 97% influenza seropositivity 
in dogs with respiratory disease at several veterinary clinics and shelters in New York and Florida.7 
Moreover, since first isolation of the virus in 2004, the Animal Health Diagnostic Center at Cornell 
University has reported CIV H3N8 infection and/or detected antibodies in dogs sampled in at least 28 
states and the District of Columbia.114 Interestingly, CIV has yet to be reported in the Canadian provinces 
except for an Ontario study, which detected CIV serum antibodies in only one dog – a greyhound from 
Florida.132 
 As influenza virus replicates in the respiratory epithelium, respiratory secretion droplets generated 
by coughing and sneezing, aerosolized secretions, and direct physical contact between infected and 
naïve individuals constitute potential routes of transmission.139 Results from several recent studies 
suggest that dogs housed in close proximity in closed-air environments are at greater risk for CIV 
exposure.112,128 For example, a CIV surveillance study at a Philadelphia shelter found 42% CIV 
seropositivity in dogs.112 In another study from Colorado, 100% (5/5) of humane shelters experiencing 
canine respiratory disease had at least one dog at the facility shedding influenza virus.131 Further studies 
found an increased risk for CIV seropositivity in Colorado household dogs that had attended canine day-
care or had been boarded within six months prior to serum sample collection.128 Additionally, stress might 
increase risk for influenza infection in dogs, as has been observed in other species.140-142  
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This chapter was published as a scientific article in the Canadian Veterinary Journal: Pecoraro HL, Lee 
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 Like shelter dogs, sled dogs are housed in close proximity with one another. They also 
experience additional stressors compared to household dogs, such as travel, prolonged endurance 
exercise in inclement weather, and exposure to harsh terrain. As such, sled dogs represent a population 
that might be particularly vulnerable to CIV infection. To determine the seroprevalence of CIV in this 
population, we sought to estimate the rate of CIV seropositivity in dogs racing at the 2010 Iditarod and to 
investigate any risk factors associated with CIV infection in racing sled dogs. 
 
MATERIALS AND METHODS 
 Sample population. We utilized a cross-sectional convenience sampling method for this study. 
All sled dogs racing in the Iditarod received a pre-race blood draw for a chemistry panel and complete 
blood count conducted by the laboratory at Providence Alaska Medical Center in Anchorage. Following 
clinical pathology analysis, laboratory personnel chose ten serum samples from each team for this study. 
Each of the 71 Iditarod teams was able to enroll up to 24 dogs for pre-race screening. Thus, a total of 
1704 dogs were eligible to participate in the current study. The sample size for a seroprevalence 
estimation of 5% was 70 dogs, assuming a 5% margin of error and a 95% confidence level.128,143. Before 
initiation, this study was reviewed and approved for conduct by the Colorado State University Institutional 
Animal Care and Use Committee. 
 Hemagglutination inhibition (HI) assay. Serum antibody titers from all samples were 
determined by HI assay, as previously described,128,136 and in accordance with procedures recommended 
by the World Organization for Animal Health (OIE). Briefly, one volume of serum was incubated at 37ºC 
for 16-20 hours with three volumes of receptor destroying enzyme (Denka Seiken Co, Tokyo, Japan) 
prepared from Vibrio cholera, which was thereafter deactivated at 56°C for 30-60 minutes. Twenty-five µl 
of treated serum was diluted with phosphate buffered saline (PBS) across a 96-well plate and mixed with 
four hemagglutinin units of a CIV isolated in Colorado in 2006 (A/canine/Colorado/148902/2006 [H3N8]). 
Chicken red blood cells at a 0.5% (v/v) were added to develop the assays. HI antibody titers were 
determined as the reciprocal of the highest dilution causing complete inhibition of agglutination. Sera 
were tested in duplicate and each assay included both positive (CIV seropositive canine serum) and 
negative (PBS) controls. For serum samples collected from dogs reported as CIV-vaccinated, HI assays 
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were conducted using two additional CIV isolates: A/canine/Colorado/224986/2006 [H3N8] and 
A/canine/Florida/43/2004 [H3N8] (kindly provided by Dr. P.C. Crawford, University of Florida) to account 
for any potential antigenic drift. For all samples, seropositivity was defined as a HI titer > 1:8, as 
previously described in other seroprevalence studies.128 
 Virus neutralization assay. Serum samples collected from dogs that had been reported as 
having received CIV vaccination were further tested for CIV antibodies by virus microneutralization assay. 
The assay was performed as previously described with slight modifications.144 Three serum samples from 
CIV-infected dogs positive for CIV antibodies on HI assay were included as positive controls, while H3 
influenza-negative canine, ferret, and mouse sera served as negative controls. Briefly, receptor 
destroying enzyme-treated serum samples were diluted across a 96-well plate two-fold in a 50 µl volume 
of diluent consisting of Dulbecco’s modified eagle medium (Sigma-Aldrich, St. Louis, MO), 1% albumin 
from bovine serum (Sigma-Aldrich), penicillin 100U/ml, and streptomycin 50 µg/ml. The diluted sera were 
incubated with an equal volume of virus (A/canine/Colorado/224986/2006 [H3N8]) at a titer of 102 50% 
tissue culture infectious dose (TCID50) per 50 µl. The 96-well plates were then incubated at 37°C, 5% CO2 
for one hour. Madin-Darby canine kidney cells were added at a concentration of 1.5 x 105 cells/ml in 
diluent with 1 µg/ml of TPCK trypsin from bovine pancreas (Sigma-Aldrich) to all wells of the 96-well plate. 
The plates were incubated at 37ºC, 5% CO2 for 20 hours before they were washed with PBS and fixed 
with 80% acetone in PBS for 10 minutes and allowed to air-dry. Plates were subjected to an ELISA assay 
to detect the presence of the viral nucleoprotein (NP) utilizing a monoclonal mouse antibody blend (clone 
A1 and A3) to influenza A NP (Millipore, Billerica, MD) and a secondary antibody of horseradish 
peroxidase-labeled goat anti-mouse immunoglobulin G (Kirkegaard & Perry, Gaithersburg, MD). The 
color was developed with 10mg of o-phenylenediamine dihydrochloride chromogen (Sigma-Aldrich) 
dissolved in 20 ml of phosphate citrate buffer with sodium perborate (Sigma-Aldrich). Plates were 
incubated approximately four to five minutes before the reaction was stopped with 1N sulfuric acid. Plates 
were read at 490 nm using a Bio-Rad Microplate reader. Results were calculated as previously 
described.144 Sera were considered positive for H3 antibody if antibody titers were ≥ 40. Negative sera at 
the lowest dilution of 1/20 were reported as ≤ 20. 
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 Collection and analysis of team data. Each musher completed a questionnaire for his/her 
racing team which requested information on the team’s medical history, such as any coughing within the 
last six months and CIV vaccination status, background on the size and the location of the kennel, and 
travel history. Additionally, questions addressed any potential interaction with other dogs, such as 
breeding and participation in sled dog competitions. Questionnaires were collected at the time of the 
team’s pre-race screening and a veterinary technician or study author was available to answer any 
questions. Descriptive statistics were compiled for each team from which serum samples were tested. 
 
RESULTS 
 Seroprevalence of CIV H3N8 in sled dogs. A total of 419 samples from 42 sled dog teams were 
tested for the presence of CIV antibodies. However, because there were matching questionnaires for only 
40 teams, the final sample size was 399 sled dogs, or 23.4% of the total 1704 dogs screened for the 2010 
Iditarod race. Surprisingly, none of the 399 serum samples tested were positive for CIV H3N8 antibodies 
based on HI assay, including sera from 39 dogs reported as vaccinated for CIV. Indeed, none of the 
serum samples exhibited hemagglutination inhibition at any of the dilutions tested (starting at the serum-
receptor destroying enzyme dilution of 1:4). Seronegativity for the presumably CIV-vaccinated dogs was 
confirmed by HI assay using two additional CIV isolates to account for antigenic variation, as well as by 
the more sensitive virus microneutralization assay. Interestingly, medical histories revealed that 10% 
(4/40) of the teams reported their dogs to be CIV-vaccinated in the months prior to the 2010 Iditarod and 
22.5% (9/40) teams indicated that at least one dog on their team had been coughing within 6 months of 
the race.  
 Team questionnaire data. As there were no positive samples, risk factor analysis for CIV in 
sledding dogs was not possible. However, descriptive statistics were compiled to characterize the social 
interactions between dogs and any points of contact among teams. The sled dogs in this study originated 
from eight states (Alaska, Colorado, Idaho, Minnesota, Michigan, Montana, Washington, and Wyoming) 
and three Canadian provinces (British Columbia, Saskatchewan, and Ontario). Additionally, 52.5% 
(21/40) of sled dog teams travelled outside their home state or province within 6 months of the 2010 
Iditarod, including to states where CIV has been detected (Colorado, Washington, and Wyoming). The 
39 
majority of sled dogs (62.5%; 25/40 teams) were housed with 50 dogs or more, and 87.5% of teams 
(35/40) were kenneled at only one location. Housing of sled dogs ranged from teams that allowed free 
roaming access inside the musher’s home, to teams that separated their dogs in designated crates within 
an enclosed building, to teams that housed sled dogs outdoors with dogs tethered next to individual 
housing structures according to guidelines established by Mush with P.R.I.D.E. 
(http://www.mushwithpride.org). During travel to racing competitions, dog confinement also varied widely. 
While many teams transported their teams in enclosed trailers, with internal dog crates facing one 
another, other teams’ traveling systems consisted of trailers with individual compartments facing outward 
to the open air, completely separating dogs from one another. Breeding, another potential point of direct 
contact among dogs, was reported in 35% (14/40) of teams, although the questionnaire did not specify 
whether breeding was within the teams’ own kennel or with dogs from an outside kennel. Interestingly, at 
least three 2010 Iditarod teams were known to include dogs acquired from humane shelters (from Alaska, 
Montana, and the Yukon Territory). Finally, all teams tethered dogs to a common chain (or cable run) 
before, during, and after competitions, allowing for additional nose-to-nose contact among team dogs. 
 Team-to-team interactions. Contact among different sled dog teams primarily consisted of any 
breeding between dogs from separate kennels (information was not requested on the questionnaire, 
though it was related to the authors during blood collection), acquisition of racing dogs from other sled 
dog teams (also reported during blood collection), and any interactions among dogs during racing 
competitions. As each team must qualify to race at the Iditarod, there is a minimum of two interactions 
with other sled dog teams a year (the qualifying and the Iditarod races). Sled dog teams typically were 
separated before the start of racing competitions and at checkpoints during races, although contact 
among teams potentially occurred along racing trails. In the year prior to the Iditarod, 52.5% of sled dog 
teams (21/40) took part in at least three long distance race competitions where other sled dog teams 
were present. In total, there were 27 races in Canada and the United States in which the racing sled 




 The results of this study demonstrate that none of the sled dogs sampled had been recently 
exposed to CIV and subsequently produced detectable antibodies to the virus. This finding is surprising 
given the fact that several of the sled dog teams that were tested are living in large, shared housing, 
reside in and travel to states where CIV infections have been reported (i.e., California, Colorado, Oregon, 
Utah, Washington, Wisconsin, and Wyoming),114 frequently compete in races where they come into 
contact with other sled dog teams, and include team members that have been adopted from humane 
shelters. Several recent studies conducted in Ontario, Iowa, Colorado, and Pennsylvania indicate that 
CIV seroprevalence in non-shelter pet dogs without a history of respiratory disease is low [0.4%,132 
0.5%,134 3.0%,130 and 3.6%,128 respectively], compared to 42% seropositivity in the Philadelphia humane 
shelter study that tested sera from dogs with and without clinical signs of respiratory disease. Therefore, 
CIV seroprevalence in sled dogs appears to be closer to that found in household dogs rather than to the 
higher level of seropositivity seen in shelter dogs. 
 It is clear that sled dogs come into direct contact with one another (both intra- and inter-team), as 
well as in indirect contact (sharing of leashes, crates, etc.). Thus, it is not understood why exactly no CIV 
positive dogs were detected. As the majority of sled dogs included in this study originated from states and 
provinces where CIV infection has yet to be reported,114 geographical location cannot be discounted. In 
spite of this limitation, CIV has been repeatedly detected in states where sled dogs that were included in 
this study live, train, travel, and race (such as Colorado and Wyoming). One important difference may be 
that, unlike shelter dogs, many sled dogs are confined outdoors where they are tethered next to separate 
housing structures. While favorable environmental temperatures (i.e., 5ºC)145 exist for influenza virus 
survival in all the states where the tested sled dogs reside, other factors such as exposure to open air and 
solar radiation might account for the lack of CIV infection in the sledding dogs tested in this study. More 
ecological studies are needed to elucidate the CIV transmission dynamics within different environmental 
settings, although it is well-known that in open-air environments, viruses and other microorganisms are 
susceptible to inactivation by a multitude of reactive chemicals.146,147 
 Another interesting finding is the fact that all the dogs reported by the mushers to be vaccinated 
for CIV also tested negative for CIV antibodies. These results were consistently negative even when 
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employing three different viruses as antigens to account for antigenic drift and two different serological 
assays (HI and virus microneutralization assays). It is important to note that it is currently unknown how 
long CIV antibodies persist in individual dogs following natural exposure or vaccination to CIV, and, 
therefore, any of the sled dogs tested in this study would have no detectable antibody if CIV antibodies 
are indeed short-lived. Despite this caveat, however, the finding that none of the reportedly CIV-
vaccinated dogs were CIV seropositive is unexpected and may be explained by several possibilities. 
Firstly, perhaps these dogs were not actually vaccinated for CIV. Although teams reported vaccinating 
their dogs in the months prior to the 2010 Iditarod race, confusion regarding whether CIV is included in a 
standard vaccination regimen is not uncommon. Secondly, it is possible that these dogs did not receive 
the recommended second booster dose or received it within days of the pre-screening blood draws when 
antibodies might not yet be present (dates of vaccination were not reported). During a recent CIV vaccine 
study, there was an average 2.5-fold geometric mean HI antibody titer difference after initial CIV 
vaccination compared to after the second CIV booster.111 Clearly, the second CIV booster induces a 
stronger antibody response than receiving only one CIV vaccine. Thirdly, as sled dogs are the equivalent 
of ultra or elite marathon runners, extreme exercise in these animals might lead to catabolism of 
endogenous protein (such as globulins) for energy, which could cause a decrease in overall serum 
antibody concentration. This notion is supported by the finding that Alaskan sled dogs exposed to 
prolonged endurance exercise demonstrated significantly decreased levels of protein concentrations in 
serum after the onset of long-distance racing compared to serum levels before the race.148 Therefore, it 
would be worth investigating differences in CIV-induced immunity among dogs of various athletic 
conditioning. Finally, it is possible that vaccination, or even past infection, did not induce an antibody 
response detectable by HI or microneutralization assay. Although the HI assay is considered the test of 
choice for virus surveillance and serological diagnosis of influenza A virus infections in animals,116,149 it is 
not the most sensitive assay for detecting influenza antibodies.150 While microneutralization assays are 
more sensitive than HI assays, the single radial hemolysis assay is still judged to be the most sensitive of 
the three serological assays.150 Future seroprevalence studies might consider using this last method if 
known vaccinates consistently test negative using the other two serological methods utilized in this study.  
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 In conclusion, this study found no CIV antibodies in serum samples collected from the racing sled 
dogs tested, despite shared housing among dogs, travel to states were CIV has been reported, and 
contact with dogs from humane shelters. However, given the potential for introduction of CIV into the sled 
dog population, continued studies are warranted to assess CIV infection among racing sled dogs and to 
further evaluate the ecology of CIV transmission and vaccine efficacy within this particular population. 
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 Canine influenza virus (CIV) (H3N8) was first detected in Florida racing greyhounds in 2004 and 
quickly spread into New York and Florida shelter dog populations.7 The transmission of influenza A 
viruses is primarily thought to be by direct or indirect contact, deposition of infectious droplets (≥ 5 µm) on 
nasal or oral mucosa, or inhalation of infectious particles (< 5 µm).139 Recent CIV seroprevalence studies 
suggest that there is an increased risk of CIV infection for dogs housed in closed-air communal 
environments,128 where promotion of efficient virus transmission by any of the aforementioned routes of 
infection is possible. Indeed, humane shelters have consistently reported high rates of CIV in dogs 
exhibiting signs of canine infectious respiratory disease or CIRD. In a New York and Florida humane 
shelter study conducted shortly after CIV emergence, up to 97% of dogs were seropositive for CIV.7 
Similarly, dogs from humane shelters in Colorado were infected with CIV in five out of five humane 
shelters reporting CIRD outbreaks in 2006 and 2007.131 More recently, in Pennsylvania, 42% of dogs with 
and without clinical signs of CIRD were CIV seropositive.112  
 Besides respiratory illness signaled by fever (>103°F), nasal/ocular discharge, non-productive, 
persistent cough, anorexia, lethargy, and weight loss,104 CIV infection in dogs might account for significant 
delays between intake into a shelter and discharge.151 In turn, increased length of stay in a humane 
shelter further impacts a pet’s chance for adoption, as the longer an animal remains in a facility, the less 
socialized the pet might become and the greater the risk of pathogen transmission.152 Considering the 
threat CIV poses to canine health and adoptability, persistence of the virus within humane shelters is 
worrisome, especially as CIV transmission dynamics are virtually unknown. Studies conducted in non-
shelter dog populations find very little CIV seropositivity in household, racing sled, and flyball tournament 
dogs,128,130,153 suggesting CIV infection to be relatively lower in dogs from the non-shelter community. In 
contrast, CIV is routinely detected in humane shelters throughout the U.S., especially in Colorado and 
New York, where surveillance studies have been recently performed.106,108,131 The discrepancy between 
CIV in community versus shelter dogs leads to more questions than answers. Particularly, what role does 
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dogs entering a facility play in CIV introduction? What factors contribute to the establishment of CIV within 
humane shelters once the virus has been introduced? Furthermore, and perhaps the most significant 
biological question, are humane shelters centers for CIV amplification? Given these questions and the 
unknown transmission dynamics of CIV, greater knowledge of true CIV prevalence in shelter dogs, as 
well as a greater understanding of the epidemiological and ecological factors contributing to CIV 
persistence within humane shelters, would help shelter veterinarians and personnel identify strategies for 
CIV prevention. For this purpose, we sought to compare CIV shedding and seroprevalence in shelter 
dogs upon shelter admission and discharge and to identify any correlates of CIV infection in U.S. humane 
shelters.  
 
METHODS AND MATERIALS 
 Animals. Prior to initiation, all studies described were reviewed and approved for conduct by the 
Colorado State University Institutional Animal Care and Use Committee. For these studies, we utilized a 
prospective convenience sampling method. The number of nasal swabs and serum samples required for 
estimation of infection rates and seroprevalence was 4680143 among six participating shelters: 
Sacramento, CA (SSPCA); Pikes Peak Region, CO (HSPPR); Tampa Bay, FL (HSTB); New York, NY 
(ASPCA); Charlestown, SC (CAS); and Austin, TX (TLAC). Shelters were chosen based on expected CIV 
rates (e.g., CA, TX, and SC had relatively lower expected CIV compared to CO, FL, and NY). To meet 
this goal, each shelter collected blood and nasal swab samples from 20 admitted and 20 discharged dogs 
each month. Generally, sampling would be performed on designated day(s) and collection occurred 
sequentially from every dog admitted to and discharged from the humane shelter until the monthly goal 
was met. All dogs, irrespective of age, breed, sex, and vaccination or health status were included, unless 
the primary caretaker determined that blood collection would be unsafe for the dog. Discharged dogs 
were dogs that had resided at the shelter for at least seven days and included dogs that were adopted out 
into the community, as well as dogs that were scheduled by the humane shelter for euthanasia. Between 
December 2009 and January 2012, over 5160 samples were collected from the six shelters.  
 Clinical samples. Matching nasal swab and serum samples were collected from shelter dogs 
(although occasional single blood or nasal swab samples were also processed). Briefly, a sterile 
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polyester-tipped swab was inserted deep into one of the nostrils and rotated to collect mucus. The swab 
samples were immediately placed in 1 ml of viral transport medium (phosphate buffered saline, 0.5% 
bovine serum albumin, 2,000 U/ml potassium penicillin G, 4 mg/ml streptomycin, 16 µg/ml gentamicin, 
and 100 U/ml nystatin) and stored at 4°C. Additionally, ~2ml of blood were drawn from either the cephalic, 
saphenous, or jugular veins, placed in an additive-free tube, and stored at 4°C. Once all samples were 
collected for the month, they were shipped to the laboratory at Colorado State University on ice overnight. 
At the laboratory, samples were immediately processed for further analysis. 
 Hemagglutination inhibition (HI) assay. In accordance with procedures recommended by the 
World Organization for Animal Health (OIE) and from previous studies,128,136 sera from blood samples 
were used to determine CIV H3N8 antibody titers by HI assay. Briefly, one volume of serum was 
incubated at 37ºC for 20 hours with three volumes of Vibrio cholera receptor destroying enzyme (Denka 
Seiken Co; Tokyo, Japan). After a deactivation period at 56°C for 60 minutes, 25 µl of treated serum was 
diluted in duplicate with phosphate buffered saline across a 96-well plate. Four hemagglutinin units of 
A/canine/CO/224986/2006 (H3N8) were incubated with the diluted sera for 45-60 minutes. To develop the 
assays, 0.5% (v/v) chicken red blood cells were added to each well and allowed to agglutinate for 25-30 
minutes. HI antibody titers were determined as the reciprocal of the highest dilution causing complete 
agglutination inhibition. Seropositivity was defined as a HI antibody titer of equal to or greater than 1:16 in 
accordance with the OIE. 
 Real time reverse transcriptase-polymerase chain reaction (rRT-PCR). Viral ribonucleic acid 
was extracted from 200 µl of viral transport medium and eluted in a final volume of 60 µl RNase-free 
water using an automated ribonucleic acid isolation system (Qiagen Qiaxtractor; Hilden, Germany) before 
storage at -80°C. The one-step rRT-PCR assay was performed as previously described.131 Briefly, a 5 µl-
aliquot of RNA template was mixed with 20 µl of mixture containing iScript One-Step RT-PCR Kit 
reagents (BioRad; Hercules, CA), 200 nmol each of the forward (5’ GAA CAC CGA TCT TGA GGC ACT 
C 3’) and reverse (5’ GGC ATT TTG GAC AAA GCG TCT AC 3’) primers to amplify 144bp of the 
influenza virus matrix gene, and 80 nmol of probe. Water and viral transport medium were used as 
negative controls, while the positive control consisted of 10 TCID50 of A/canine/CO/224986/2006 (H3N8). 
For consistency, the epMotion Ep5070p (Eppendorf; Hamburg, Germany) automated system was used to 
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load 96 well plates before amplification and detection by Mastercycler Realplex (Eppendorf) using 
previously described conditions.131  
 Prevalence estimates. True prevalence was estimated by stochastic latent class analysis, as 
described by Branscum et al.126 using Gibbs sampling,127 in WinBUGS statistical software.129 
Assumptions for this method include constant sensitivity and specificity of the diagnostic test used, as 
well as only one population sampled. For prior distributions, the rRT-PCR mode was set at 0.96 for 
sensitivity and 0.74 for specificity at a 95% probability interval, based on previous studies.121,131 As each 
shelter is located in a distinct geographical region constituting a unique population, true prevalence was 
determined separately for each shelter. 
 Model development and analysis. Logistic regression was used to evaluate possible risk 
factors for CIV shedding and seropositivity as indicated by positive nasal swabs by rRT-PCR and HI 
assay, respectively. As temporal, spatial, and seasonal patterns have been observed with human 
influenza A virus,154,155 variables of interest included number of days in the shelter before sample was 
taken, the geographical region of the shelter, the study year, and the sampling month. Other data 
collected for analysis included the type of sample (admission/discharge), whether the dog received a CIV 
vaccination upon admission, whether the shelter quarantined incoming dogs for over seven days, whether 
the shelter accepted dogs transferred from out of state, whether the shelter isolated apparently sick dogs, 
whether the shelter adhered to an all-in/all-out room protocol, whether the dogs were allowed to co-
mingle or were ever housed with one-another, and the size of the shelter.  
 As the emerging consensus is that CIV is being propagated in endemic regions due to repeated 
introduction of CIV-infected dogs into humane shelters and subsequent dog-to-dog transmission within 
the facility,108 we proposed two sets of hypotheses to explain CIV risk in shelter dogs. The first model set 
included 14 a priori models (including an intercept-only model as a model of no effect) to assess the 
associations between CIV and region and time. Recent research suggests that increased length of stay 
within a shelter is related to CIV seropositivity within a metropolitan humane shelter,112 while, regionally, 
CIV has been consistently isolated from shelter dogs in Colorado, New York, and Florida.106,108,131 
Furthermore, Hayword et al.108 reported genetic distinction of CIV isolates from humane shelters located 
within the same city. Proposed hypotheses for explaining CIV shedding and seropositivity status within 
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the dataset included geographical region (west=1, east=2, southeast U.S.=3), vaccination status (no=0, 
yes=1), days in the shelter before sample collection (continuous variable), year of the study (year 1=1, 
year 2=2), sampling month (1-12, corresponding to month of year), as well as additive effects and 
interactions among these variables. The second model set consisted of 9 a priori models (including an 
intercept-only model) used to assess associations between CIV and within-shelter dog-interactions, as 
previous studies have suggested CIV transmission among dogs to be due to direct contact.113,115 
Proposed hypotheses included co-mingling/co-housing (no=0, yes=1), days in the shelter (continuous), 
and sampling month (1-12), plus additive effects and interactions between co-mingling/co-housing and 
days and month. The specific shelter itself was not considered in any of the models to avoid collinearity 
with other explanatory variables. Additionally, there was lack of variability among shelters for several of 
the factors of interest, including the length of time each dog was quarantined upon admission, shelter 
size, isolation protocols, and other shelter practices. We, therefore, did not evaluate the effect these 
variables on CIV outcomes. As the Colorado and New York shelters were the only shelters within their 
respective regions with positive results, the Florida and South Carolina shelters were used to represent 
the southeast region for the within-shelter dog-interaction models.  
 All together, four model sets were analyzed by logistic regression using ProcLOGISTIC in SAS 
9.3:156 (1) temporal-spatial effects on CIV-shedding, (2) temporal-spatial effects on CIV-seropositivity, (3) 
within-shelter dog-interaction effect on CIV-shedding, and (4) within-shelter dog-interaction effect on CIV-
seropositivity. Logistic regression models in all model sets were estimated from the second order Akaike 
information criterion (AICc),157,158 calculated using the following equation: 
AICc = [-2(log-likelihood) + 2K] + [2K(K+1)/n-K-1], 
where K represents the number of estimators and n the number of samples in the model. After calculation 
of the AICc estimates, model selection and multi-model inference were performed as described below. 
 Model selection and multi-model inference. We used an information-theoretic approach159 
using AIC160,161 for model selection and multi-model inference. AICc values were ranked low to high and 
the model with the lowest AICc was considered to have the best strength of evidence. Each candidate 
model (i) was compared and weighted (ω) to estimate the probability that the top-ranking model was the 
best model given the dataset. Additionally, parameter estimates were averaged across all models for 
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variables in the top models to calculate the parameter estimates (β[≃]), unconditional standard errors 
(SE), and 95% confidence intervals (CI).159 Finally, to explain model variance in the dataset, we include 
the re-scaled R-square from each of the models analyzed by logistic regression.156 
 
RESULTS 
 Geographic distribution. There were a total number of 5161 serum and 5182 nasal swab 
samples from the six humane 
shelters (Table 6-1). Samples per 
shelter ranged from ~700 (South 
Carolina) to ~1000 (Colorado) 
and all shelters, except California 
and Texas, submitted more intake 
samples than discharge samples. 
As expected, the New York and 
Colorado shelters had the highest 
numbers of both CIV 
seropositivity and nasal shedding 
(Figure 6-1). The Florida humane 
shelter, however, had much lower 
than expected CIV nasal 
shedding, given the fact that CIV 
first emerged in the state and 
previous Florida shelter studies 
showed relatively higher prevalence.7 On the other hand, the humane shelter in South Carolina had more 
than expected CIV nasal shedding, which can be attributed to a CIV outbreak during the first months of 
sample collection. After these initial CIV positive nasal swabs, only two CIV positive serum samples were 
collected from South Carolina throughout the remainder of the study. Both California and Texas had no 
Table 6-1. Number of tested nasal and serum samples from 
admitted and discharged shelter dogs, Dec 2009 to Jan 2012. 
Shelter Nasal swabs Serum samples 
 Admitted Discharged Admitted Discharged 
CA 411 443 420 442 
CO 573 462 564 460 
FL 575 376 574 374 
NY 498 368 489 363 
SC 419 288 419 287 
TX 299 470 298 471 





Figure 6-1. Proportion of dogs sampled each month of the study 
that were shedding CIV detected by real time RT-PCR (PCR+). 
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CIV seropositive samples and 
California had only one dog shedding 
CIV upon admission into the shelter 
(April 2010) throughout the entire 
study. True prevalence estimates 
(Table 6-2) corroborate other 
reports suggesting CIV is endemic in Colorado and New York106,108,131 with prevalence estimates of 2.7% 
and 2.5% for these shelters, respectively. The CIV positive nasal swabs collected from South Carolina in 
the first two months of the study may explain the higher CIV shedding prevalence estimates for the South 
Carolina shelter (1.9%) compared to the Florida shelter (0.7%). The two shelters with one or no CIV 
shedding dogs (Texas and California) had the lowest estimates for CIV prevalence (0.12-0.16%). 
 Community-shelter dog transmission. Differences between intake and discharge CIV shedding 
rates depended on the humane shelter sampled (Figure 6-2). For Colorado shelter dogs, there were six 
times more dogs (8.9%) leaving the facility shedding 
CIV than dogs that entered (1.4%). In contrast, New 
York dogs were more likely to be shedding virus upon 
admittance (6.9%) rather than upon discharge (1.1%). 
In the other two shelters (Florida and South Carolina) 
where CIV was detected in nasal swab samples, 
intake and discharge dogs had similar rates of 
shedding (ranging from 1.2% to 3.8%). In total, 
66/2768 (2.4%) dogs shedding CIV were admitted into 
the shelters and 57/2418 (2.4%) shelter dogs were 
discharged while shedding the virus. These numbers 
included dogs from all four positive shelters, plus the 
one positive dog at the California shelter. There were a total of 92 seropositive dogs upon admission (of 
2765 – 3.3%) and 97 dogs (of 2408 – 4.0%) upon discharge. Three hundred twenty five dogs were known 
vaccinates, and received at least one dose of the CIV vaccine upon admittance into the shelter. Of these, 
Table 6-2. True prevalence median probability estimates 
(95% probability intervals) based on the proportion of CIV 
shedding in U.S. shelter dogs. 




CA 0.001 0.002 (0.0-0.009) 
CO 0.047 0.027 (0.020-0.085) 
FL 0.013 0.007 (0.0-0.027) 
NY 0.044 0.025 (0.020-0.082) 
SC 0.032 0.019 (0.010-0.062) 






Figure 6-2: Proportion of sampled admitted and 
discharged dogs in U.S. humane shelters. 
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125 were sampled on discharged. Interestingly, only five of the 125 vaccinated discharged dogs were 
seropositive (three dogs that received two doses and two dogs that received only one vaccine dose). 
Additionally, 51 dogs received both the initial CIV vaccination and a booster 7-14 days later while residing 
in the shelter. All but one of these were seronegative upon discharge, while three of these were shedding 
CIV upon discharge. 
 Risk factor analysis. After excluding dogs from the California and Texas shelters, any samples 
with missing information, and 148 duplicate samples (dogs that had been sampled both on intake and 
discharge), there were a total of 3407 nasal swab and 3385 serum samples for the temporal-spatial 
analyses. There were 1608 nasal swab and 1604 serum samples from the Southeast shelters. For the 
first model set, temporal-spatial effects contributing to CIV shedding, the year x region interaction was 
ranked the highest and, thus, appears to have the best strength of evidence with a model weight (ωi) of 
0.93 for explaining nasal viral shedding in shelter dogs from 2009-2012 (Table 6-3). This model indicates 
CIV shedding was highly associated with both the region where the dog resided and the year of sampling. 
The model-averaged estimate for the effect of year suggests shedding was more likely during the first  
 
Table 6-3. Candidate model set and ranking of models examining temporal-spatial factors contributing 
to CIV-shedding in U.S. shelter dogs. 
Model (i) R2 log(L) K AICc Δi ωi 
year*region 0.04 -480.18 4 968.37 0.00 0.93 
vax+region+days+year+month 0.04 -481.30 5 974.62 6.25 0.04 
vax+region+days+year 0.04 -482.80 5 975.61 7.23 0.03 
vax+region+days 0.03 -487.53 4 983.08 14.70 0.00 
year+month 0.02 -490.40 3 986.80 18.43 0.00 
year 0.02 -491.49 2 986.99 18.62 0.00 
vax*days 0.02 -490.01 4 988.03 19.66 0.00 
days+region 0.02 -492.43 3 990.87 22.50 0.00 
region 0.01 -494.95 2 993.90 25.52 0.00 
vax 0.01 -494.96 2 993.92 25.55 0.00 
month+region 0.01 -493.98 3 993.97 25.60 0.00 
days 0.01 -496.03 2 996.06 27.68 0.00 
Intercept-only -- -499.37 1 1000.75 32.37 0.00 
month 0.00 -498.45 2 1000.90 32.53 0.00 
 
R2: Adjusted R2 
log(L): Log likelihood 
K: Number of parameters 
AICc: Second order Akaike information criterion 
Δi: Difference between model and best model 
ωi: Weight of model 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year of the study (β[≃]=0.55, unconditional SE=0.06, 95% CI=0.43, 0.66), while for region there was 
more shedding in the eastern shelters as a whole compared to the Colorado shelter (β[≃]=0.07, 
unconditional SE=0.67, 95% CI=-1.38, 1.24). The next best model (i.e., next highest ranked model) for 
CIV nasal shedding included all of the variables of interest (vaccination status, region, days in shelter, 
year of study, and month) and had a ωi of 0.04. It is important to note that for both of these models, the 
adjusted R-square162 value is low (0.04). For CIV-seropositivity in U.S. shelter dogs, the highest-ranking 
model contained vaccination status (β[≃]=0.04, unconditional SE=0.13, 95% CI=-0.21, 0.28), region (
β[≃]=-0.73, unconditional SE=0.53, 95% CI=-
1.76, 0.30), days in shelter (β[≃]=0.02, 
unconditional SE=0.01, 95% CI=0.01, 0.04; 
Figure 6-3), and year of study (β[≃]=0.11, 
unconditional SE= 0.09, 95% CI=-0.07, 0.28), 
and had the best strength of evidence with a 
ωi of 0.42 (Table 6-4).  
 
 
Table 6-4. Candidate model set and ranking of models examining temporal-spatial factors contributing 
to CIV-seropositivity in U.S. shelter dogs. 
Model (i) R2 log(L) K AICc Δi ωi 
vax+region+days+year 0.09 -652.05 5 1314.12 0.00 0.42 
days+region 0.09 -654.62 3 1315.25 1.13 0.24 
vax+region+days+year+month 0.09 -651.77 6 1315.57 1.45 0.20 
vax+region+days 0.09 -654.09 4 1316.20 2.08 0.15 
year*region 0.00 -669.36 4 1346.73 32.61 0.00 
region 0.06 -672.29 2 1348.58 34.46 0.00 
month+region 0.06 -672.02 3 1350.05 35.93 0.00 
vax*days 0.02 -694.81 4 1393.64 79.52 0.00 
days 0.02 -695.75 2 1395.51 81.39 0.00 
year 0.00 -703.92 2 1411.84 97.72 0.00 
year+month 0.00 -703.68 3 1413.37 99.25 0.00 
Intercept-only -- -706.15 1 1414.30 100.18 0.00 
vax 0.00 -705.79 2 1415.59 101.47 0.00 
month 0.00 -705.86 2 1415.73 101.61 0.00 
 
 
Figure 6-3. Probability of seropositivity increased with 
increased length of stay within humane shelters.  
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In this analysis, the top four models explain 95% of the variation (i.e., the top four ωi’s have a sum of 
≥95%), and, again include a combination of the variables from the highest-ranked model. The last two 
model sets examining the effects of within-shelter dog-interactions on CIV -shedding and -seropositivity, 
exhibited similar patterns. In the analysis for CIV-shedding, the month x co-mingling/co-housing 
interaction was the highest-ranking model with a model weight (ωi) of 0.92 and had an R-square of 0.07 
(Table 6-5). The model-averaged estimate for the effect of co-mingling/co-housing suggests shedding 
was more likely in shelters that allowed dogs to interact (β[≃]=0.25, unconditional SE=0.34, 95% CI=-
0.42, 0.92) and during certain months of the year (β[≃]=-0.20, unconditional SE=0.08, 95% CI=-0.35, -
0.04).  The CIV seropositivity model set had slightly higher R-square values (Table 6-6). Here, four 
models contributed to 95% of the variation, and included an additive or interactive combination of days in 
Table 6-5. Candidate model set and ranking of models examining within shelter dog interactions 
contributing to CIV-shedding in U.S. shelter dogs. 
Model (i) R2 log(L) K AICc Δi ωi 
month*cohm 0.0700 -154.27 4 316.55 0.00 0.92 
days+month+cohm 0.0484 -157.52 4 323.06 6.50 0.04 
cohm+month 0.0396 -158.83 3 323.67 7.12 0.03 
days+cohm 0.0320 -159.98 3 325.97 9.42 0.01 
cohm 0.0235 -161.24 2 326.49 9.94 0.01 
days*cohm 0.0322 -159.95 4 327.92 11.37 0.00 
month 0.0133 -162.77 2 329.55 12.99 0.00 
days 0.0124 -162.91 2 329.82 13.27 0.00 
Intercept-only -- -164.76 1 331.51 14.96 0.00 
 
Table 6-6. Candidate model set and ranking of models examining within shelter dog interactions 
contributing to CIV-seropositivity in U.S. shelter dogs. 
Model (i) R2 log(L) K AICc Δi ωi 
days 0.1039 -40.47 2 84.94 0.00 0.53 
days+cohm 0.1094 -40.22 3 86.46 1.52 0.25 
days+month+cohm 0.1103 -40.18 4 88.38 3.45 0.10 
days*cohm 0.1094 -40.22 4 88.47 3.53 0.09 
Intercept-only -- -45.03 1 92.05 7.12 0.02 
month 0.0022 -44.93 2 93.86 8.93 0.01 
cohm 0.0000 -45.03 2 94.06 9.12 0.01 
cohm+month 0.0022 -44.93 3 95.87 10.93 0.00 
month*cohm 0.0043 -44.84 4 97.70 12.76 0.00 
R2: Adjusted R2 
log(L): Log likelihood 
K: Number of parameters 
AICc: Second order Akaike information criterion 
Δi: Difference between model and best model 
ωi: Weight of model 
 
53 
shelter (β[≃]=0.05, unconditional SE=0.03, 95% CI=-0.02, 0.11), co-mingling/co-housing (β[≃]=-0.04, 
unconditional SE=0.27, 95% CI=-0.58, 0.49), and month (β[≃]= 0.00, unconditional SE=0.01, 95% CI=-
0.02, 0.02). However, the results of the within-shelter dog-interaction model sets should be interpreted 
cautiously, as the total numbers of CIV-shedding and -seropositive dogs were only 34 and 7, respectively.  
 
DISCUSSION 
 CIV continues to be a threat to the health and welfare of shelter dogs. The studies described here 
are among the first to evaluate the CIV status of community dogs entering humane shelters and shelter 
dogs being discharged back out into the community. It is clear that CIV is endemic in the areas where the 
Colorado and New York humane shelters are located, namely, the greater Colorado Springs and New 
York City regions.106,108,131 What is less apparent is to what extent CIV affects the other regions in our 
study. Despite not detecting CIV from any of the dogs sampled at the Texas shelter, there were PCR-
confirmed CIV cases in Texas near the end of the sampling period.114 Interestingly, CIV was last 
confirmed in Florida dogs by the Cornell Diagnostic Laboratory in 2008,106,114 while a CIV isolate was 
sequenced from a dog in California in 2006.106 Therefore, despite the results from this study, whether 
negative in the cases of California and Texas or positive in the case of Florida, no region should be 
considered entirely safe from the threat of a potential CIV epidemic. The true prevalence estimates reflect 
this as well, as none of the shelters were completely CIV-free. 
 The intake and discharge data from each shelter suggest that the transmission dynamics 
between the community and shelter dog populations vary among individual shelters. Clearly, CIV is 
entering humane shelters from community dogs; all of the shelters, except Texas, had at least one intake 
dog that was shedding CIV. Similarly, the shelters with consistently positive nasal swabs released CIV 
shedding dogs back into the community. It follows that humane shelters likely facilitate the amplification of 
CIV, as has been suggested in other studies examining enclosed-environments.128 As such, the need for 
an effective vaccine becomes undeniable. However, due to the fact that only 325 dogs in the study 
received one or more CIV vaccinations, evaluating the effect the vaccine had on the shelter dog 
population is difficult. It is interesting that only one of the twice-vaccinated dogs was seropositive upon 
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discharge from the shelter and three discharged dogs were shedding CIV after receiving two CIV vaccine 
doses. The negative HI titers might be due to early sampling before CIV antibodies are detectable. 
Furthermore, two of the three vaccinated dogs shedding CIV upon discharge might have shed less CIV 
than if they had not been vaccinated, as the virus detected in their nasal swab samples was close to the 
negative threshold point (1000 matrix gene copies) for rRT-PCR. However, the date these dogs were 
infected is unknown, as is when during the course of CIV-infection they were sampled. It is also important 
to note that the best candidate models containing vaccine variables were in combination with other 
temporal-spatial variables. The models with only vaccine status have very little evidence of effect for our 
datasets. This suggests that receiving the vaccine alone is not associated with increased or decreased 
risk of CIV. Therefore, especially as dogs may not reside in the shelter long enough to receive the 
recommended CIV vaccine booster and as CIV isolates are known to cause subclinical infection in 
experimental dogs,115 further research on the potential of the CIV vaccine to reduce CIV infection in 
shelters is warranted.  
 In dogs that were shedding CIV, several risk factors have been identified. For CIV-shedding in 
U.S. shelters, there was evidence suggesting CIV depends on space (region) and time (year). From our 
data, most of the positive Colorado nasal swabs were collected during the first year of the study, before 
detectable shedding tapered off by early study year two. The Colorado shelter sampled 90% (44/49) of 
their CIV-shedding dogs during the first year and submitted the last positive nasal swab March 2011. The 
opposite is true for the New York shelter. Few shedding dogs were sampled in study year one, while 
positive swabs gradually increased over time (in fact, 25 of the 36 total positive samples for New York 
were collected after January 2011). The South Carolina and Florida shelters show a similar pattern as 
well. South Carolina submitted all of their positive nasal swab samples during a very short period in study 
year one (December 2009 through January 2010), while the majority (9/12) of Florida’s positive swab 
samples were collected during those same two months.  
 Spatio-temporal patterns for influenza A viruses are not new,154,155,163 and true prevalence rates 
estimated over the entire study period might not accurately reflect the trends seen in the data. It appears 
that CIV, instead of being a pathogen persisting at low levels in endemic shelters, actually falls more in 
line with an ebb and flow pattern – where outbreaks occur at one shelter in one region and wane before 
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CIV emerges in an entirely different shelter in another region. Such a pattern also takes into account the 
movement of infected dogs along a network, as seen during the emergence of CIV,7 as well as the co-
mingling/co-housing x month effect seen in the within-shelter dog-interaction models. During months 
when CIV-shedding was detected in the Southeast region, separating dogs appeared to decrease CIV-
infection. This is also reflected by the odds ratio: no co-mingling/co-housing during months of CIV-
infection reduced risk by 33% (OR 0.67; 95% Confidence Interval [CI] 0.51, 0.89).  
 CIV-seropositivity was also associated with the additive effects of space (region) and time (year 
and month), as well as vaccine status and number of days spent in the shelter. However, odds ratios from 
the multivariable model for the last two factors suggest that, individually, they neither increase nor 
decrease CIV-seropositivity: vaccination (OR 1.00, 95% CI 0.50, 2.00) and days (OR 1.02, 95% CI 1.01, 
1.02). Days in shelter is particularly interesting, as it has been previously associated with CIV in shelter 
dogs.112 However, when the dataset is narrowed to evaluate the within-shelter dog-interaction effect, days 
in the shelter before sampling actually becomes the common variable among the best models. Thus, in 
shelters where dogs are allowed to interact for longer periods of time, the more risk they have of 
becoming CIV-seropositive. As CIV antibodies in experimentally-infected and sentinel dogs have been 
noted between days 7-12 post-challenge,115 a length of shelter stay over 7 days allows time for 
seroconversion. This might account for some of the seropositive discharged dogs, especially in the New 
York shelter where dogs infected upon intake would have seroconverted if they were in the shelter for 
seven days or longer.  
 Although several risk factors identified here have been reported elsewhere,112,113 other variables 
not included in these models are likely contributors to CIV within shelters. The low R-square values 
suggest that some other factors are in play. A number of variables could not be modeled in our analysis, 
including quarantine, isolation, and all-in/all-out practices, as well as the effect of accepting dogs 
transferred from out of state and size of the shelter. For example, New York was the only shelter that 
quarantined their animals for seven days or more. Coincidentally, New York was also the only shelter that 
saw a six-fold decrease in CIV-positive dogs upon discharge compared to intake. It should also be noted 
that New York was the smallest shelter in the study (750-800 annual dog intake). On-the-other-hand, 
Colorado, which was one of the largest participating shelters (11,000 annual dog intake), had only a 24-
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48 hour quarantine in place during the study period and had a six-fold increase of CIV-positive dogs upon 
discharge compared to intake. The effects of size and quarantine could not be modeled here due to lack 
of intra- and inter-shelter variability. However, these possible effects should be taken into account during 
the research design process of any future studies. 
 In conclusion, our results suggest that community dogs are a source of CIV introduction into 
humane shelters and that, once CIV has become established, dog-to-dog transmission maintains CIV 
within the shelter for a short-period of time (1-9 months), as evidenced by CIV-positive discharged dogs 
from the shelters sampled in our study. As a disease of space and time, modeling could be helpful for 
predicting future CIV outbreaks; however, other risk factors are still in need of investigation. Ultimately, it 
is hoped that this report will be used to begin the process of identifying preventative and control measures 




CHAPTER SEVEN: GENOME EVOLUTION AND ANTIGENIC VARIATION OF CANINE INFLUENZA 
VIRUSES H3N8 IN DOGS 
 
INTRODUCTION 
 Although serological evidence suggests canine influenza virus (CIV) (H3N8) has been circulating 
in U.S. dogs since as early as 1999,138 it was not until 2004 that the virus was first isolated from Florida 
racing greyhounds exhibiting signs of infectious respiratory disease.7 Early phylogenetic analyses showed 
CIV, an influenza A virus in the family Orthomyxoviridae, to be closely related to contemporary equine 
influenza viruses (EIV) of the Florida Clade 1 sublineage.7,8 From the emerging CIVs, ten amino acid 
substitutions within the hemagglutinin (HA), neuraminidase, nucleoprotein, and polymerase proteins were 
identified.8 Unlike other horse-to-dog EIV transmission events in which dogs have been only incidentally 
infected,9,98 CIV represented a new threat to canine health, as the virus rapidly spread to naïve dogs 
throughout the racing track circuit,7,103 animal shelters,7,112,131 and other boarding facilities.104 Studies have 
shown that, in spite of successful experimental EIV and CIV infections in both equine and canine 
hosts,105,109,110,115 influenza species specificity is currently being maintained in naturally-infected horses 
and dogs.106 Indeed, CIV isolates sequenced between 2005 and 2008 share the same ten amino acid 
substitutions originally identified in early Florida CIV, as well as an additional nine amino acid 
substitutions among the influenza proteins106 (three within the HA alone). These findings suggest that CIV 
continues to evolve from both its canine and equine influenza predecessors. 
 Hemagglutinin, one of two surface glycoproteins on influenza A viruses, has several important 
functions, including mediation of receptor binding, host cell entry, and membrane fusion.164 Given its vital 
role during influenza infection, it is not surprising that the HA protein is also the main target for antibody 
attachment and virus neutralization.107,165 Five antigenic regions (sites A-E) have been identified in the HA 
subtype 3 (H3) HA1 subunit protein.82,83,166-168 As influenza is a negative-sense single-stranded RNA 
virus, amino acid substitutions are common throughout the hemagglutinin protein. However, mutations 
within the antigenic regions have been associated with immune escape or antigenic drift,84 which can 
result in vaccine failure and increased host susceptibility to influenza infection. Historically, antigenic drift 
has had epidemiological impact when four or more amino acid substitutions are located within at least two 
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of these antigenic regions.84 Antigenic drift has been reported in human H3 influenza viruses,166,168 with 
influenza strains clustering into antigenic groups over time. For example, influenza A H3N2 viruses 
isolated from humans between 1968 and 2003 formed 11 distinct antigenic clusters.168 Equine influenza 
viruses, in contrast, clustered into only three antigenic groups over the same time period,24 while 
antigenic drift has yet to be detected in CIVs isolated from dogs.128,169  
 However, with the widespread use of a recently developed killed CIV vaccine,111 continual 
molecular evaluation of circulating CIVs is necessary for monitoring antigenic drift, caused either by herd 
immunity of naturally infected and vaccinated animals, and by the high mutation rate inherent to RNA 
virus replication. Furthermore, as CIV emerged only within the last decade, evolutionary relationships 
among CIV isolates, as well as between CIV and other influenza A viruses, are continually being 
evaluated and characterized.7,8,106,108 By analyzing the HA nucleotide and protein sequences of the first 
CIVs isolated from Florida dogs, other published CIV H3N8 strains isolated from across the U.S., and 
newly isolated CIVs from CIV-epidemic and -endemic U.S. regions, we are able to further describe the 
evolution of CIV since it first emerged in 2004, as well as report antigenic variations that could possibly 
result in the first clustering of antigenically distinct CIVs. The studies described here add to our general 
knowledge of influenza A virus evolution and, in particular, expand our understanding of CIV and its threat 
to canine health. 
 
METHODS AND MATERIALS 
 Animals. Dogs residing in six U.S. shelters participated in this prospective study. The six shelters 
were located near or within metropolitan centers (Sacramento, CA; Colorado Springs, CO; Tampa Bay, 
FL; New York, NY; Charlestown, SC; and Austin, TX) and were part of a larger CIV surveillance study 
conducted December 2009 to January 2012.170 Shelters were chosen in regions that were considered 
CIV-endemic (CO, FL, NY) and -epidemic (CA, SC, TX). Nasal swabs were taken from approximately 40 
dogs every month per shelter and all dogs, irrespective of age, breed, sex, and vaccination or health 
status, were considered eligible to participate. Prior to initiation, all studies were reviewed and approved 
by CSU IACUC.  
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 Clinical samples. Nasal swab samples were collected from dogs on-site at each humane 
shelter, as previously described.131,170 Samples were refrigerated at 4°C and shipped monthly to Colorado 
State University Veterinary Teaching Hospital (CSU VTH). Upon arrival in the laboratory, 200µl of nasal 
swab viral transport medium was removed from each sample and placed in a 96-well block for later 
ribonucleic acid (RNA) isolation. The remaining sample, along with the samples in the 96-well block, were 
immediately stored at -80°C until further processing. 
 Real time RT-PCR assay. Using an automated RNA isolation system (Qiagen Qiaxtractor; 
Hilden, Germany), viral RNA was extracted from the 200µl viral transport medium aliquots and eluted in a 
final volume of 60µl water. A one-step real time RT-PCR assay developed by members of or laboratory 
was performed to identify any CIV-positive clinical samples, as previously described.131 Briefly, a 5 µl-
aliquot of RNA template was mixed with 20 µl of mixture containing iScript One-Step RT-PCR Kit 
reagents (BioRad; Hercules, CA), 80 nmol of probe, and 200 nmol of forward (5’ GAA CAC CGA TCT 
TGA GGC ACT C 3’) and 200 nmol of reverse (5’ GGC ATT TTG GAC AAA GCG TCT AC 3’) primers to 
amplify 144bp of the conserved influenza A virus matrix (M) gene. Water and viral transport medium were 
used as negative controls, while the positive control consisted of 10 TCID50 of A/canine/CO/224986/ 
2006 (H3N8). An epMotion Ep5070p (Eppendorf; Hamburg, Germany) automated system was used to 
load 96 well plates before amplification and detection by Mastercycler Realplex (Eppendorf), using 
previously described conditions.131 
 Virus isolation. All real-time RT-PCR CIV-positive nasal swabs were stored at -80°C until virus 
isolation could be performed. Aliquots of 150-200 µl thawed viral transport medium were injected by 
candlelight into the allantoic cavities of three 10-day old embryonated chicken eggs. In addition, 50 µl of 
nasal swab sample was inoculated into MDCK cells on 6-well plates in duplicate. Inoculation medium 
contained both antibiotic (gentamicin for the egg inoculation and penicillin and streptomycin for the cell 
culture inoculations) and antifungal (amphotericin B) agents, as previously described.131 Each isolate was 
blind-passaged twice (for a total of three passages) using 200 µl of the previous passage and evaluated 
for CIV by hemagglutination inhibition (HI) assays. All first-passaged and HI-positive isolates were 
additionally tested for presence of the influenza M gene by real-time RT-PCR.  
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 Hemagglutination Inhibition Assays. In accordance with procedures recommended by the 
World Health Organization,171 and as described in previous studies,128,136,170 receptor-destroying enzyme-
treated sera from blood samples were used to determine CIV H3N8 antibody titers by HI assay. Briefly, 
four hemagglutinin units per 25µl of H3N8 antigen viruses were incubated with diluted sera for 45-60 
minutes and then developed using 0.5% (v/v) chicken red blood cells for 30 minutes. HI antibody titers 
were determined as the reciprocal of the last dilution of antiserum that completely inhibited agglutination. 
Seropositivity was defined as a HI titer of greater than or equal to 16, as in previous seroprevalence 
studies.170 
 Sequencing. The full-length HA protein-coding region for each isolated virus was amplified by a 
two-step RT-PCR. Briefly, extracted viral RNA was reverse transcribed using SZAHA primers125 and 
SuperScript™ III reverse transcriptase (Gibco/Invitrogen, Carlsbad, CA) before hemagglutinin cDNAs 
were amplified by PCR using Platinum® Taq DNA polymerase high fidelity (Gibco/Invitrogen). PCR 
products were obtained by direct cycle sequencing using ABI Big Dye (PE Applied Biosystems, Foster 
City, CA) and sequenced at the Proteomic and Metabolomics Facility at Colorado State University 
(http://www.dnatools.com). Nucleotide sequences of RNA from the shelter dog study, as well as several 
Colorado and Wyoming CIVs isolated in our laboratory since 2006, were compiled de novo using Genious 
Pro software172 and deposited into GenBank under accession numbers JX235372 through JX235394.  
 Genome and antigenic evolutionary analyses. Each nucleotide sequence was translated to 
protein using the ExPASy Bioinformatics Resource Portal (http://web.expasy.org/translate/) before both 
nucleotide and amino acid alignments were assembled using the Kyoto University Bioinformatics Center 
multiple sequence alignment on-line tool (http://www.genome.jp/tools/clustalw/). All available CIV (H3N8) 
full-length HA sequences published up until 25-Jun-2012 were downloaded from the Influenza Virus 
Resource, National Center for Biotechnology Information (NCBI) database. Additionally, HAs of viruses 
previously sequenced by members of our laboratory (GenBank accession numbers HQ917678–
HQ917681) were included. In total, there were 62 (19 new shelter, 9 Colorado and Wyoming strains 
previously isolated by members of our laboratory, and 34 published) HA amino acid sequences imported 
into MEGA 5.05173 for phylogenetic analysis. Neighbor-joining trees were constructed using a 1000-
replicate bootstrap analysis. To determine selection pressure, the Datamonkey webserver174,175 using the 
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HyPhy package176 was utilized to evaluate the nucleotide sequences from 58 (17 shelter, 8 previously 
sequenced in our laboratory, and 33 published) isolates; nine nucleotide sequences were identical to 
other isolates and were excluded from analysis. As viral populations often do not meet the assumption for 
using the ratio of non-synonymous to synonymous calculation (dN/dS), where a dN/dS ≥ 1 indicates 
positive selection pressure, because more than two mutations might segregate at a single site in viral 
populations,177 we used the mixed-effects model for evolution (MEME),178 using the HKY85 nucleotide 
substitution bias model. This method accounts for episodic selection at each individual amino acid site, 
rather than at only the node or branch alone.178 
 Antigenic regions were identified according to sites reported for human and equine influenza H3 
viruses.82,83,166-168 Additionally, to assess antigenic variability among CIV isolates within U.S. dogs, we 
performed a series of HI assays. Serum samples tested included CIV-seropositive serum samples from 
the Colorado, Florida, New York, and South Carolina humane shelters. Five different antigens were 
included: one isolate from emerging CIV (A/canine/FL/43/2004), two CIVs isolated during outbreaks from 
2006- to 2007 in Colorado and Wyoming (A/canine/CO/224986/2006 and A/canine/WY/86033/2007), and 
recent CIV isolates from humane shelters located in two geographically distinct regions 
(A/canine/CO/863160/2010 and A/canine/NY/6977983/2010).  
 
RESULTS 
 Virus isolation. Over 5100 nasal swab samples were collected from shelter dogs entering and 
exiting the six participating humane shelters over the study period. Of these, 111 were positive upon real 
time RT-PCR for the influenza M gene (Table 7-1). After three passages in both embryonated chicken 
eggs and MDCK cells, 19 viruses 
(17%) were isolated and their HA 
genes sequenced. The majority of 
these (11/19) were grown in 
allantoic fluid only, while one was 
grown in cell culture only, and 
seven viruses grew in both culture 
Table 7-1. Viruses isolated from dogs residing in humane 









California 854 1 0 
Colorado 1037 38  7 
Florida 953 12 0 
New York 863 37 11 
South Carolina 708 23 1 
Texas 771 0 0 
TOTAL 5186 111 19 
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systems. Most of the isolates were from the Colorado and New York shelters, although one virus each 
was isolated from the Florida and South Carolina shelters. Interestingly, all of the Colorado isolates were 
obtained in the first year of the study (2009-2010), while all of the New York viruses were from nasal 
swabs collected during study year two (2010-2011) (Table 7-2). Additionally, the South Carolina virus was 
collected during the CIV-outbreak that occurred in the South Carolina shelter the first month of the study 
(December 2009). The other viruses listed in Table 7-2 were isolated from either pet dogs seen at the 
CSU VTH or were collected from dogs residing at Colorado and Wyoming humane shelters during 
reported outbreaks of canine infectious respiratory disease from 2006 to 2007. 
 
 Genetic evolution of CIV. The phylogenetic analysis of HA amino acid sequences suggests that 
CIV is diverging into two genetically distinct clades (Figure 7-1). From the bootstrap consensus, the New 
Table 7-2. Canine influenza viruses isolated from nasal swabs collected from dogs 2006- 2011. 
Strain Date collected Passage* Location 
A/canine/CO/224986/2006 06-Jun-06 C3 CSU VTH† 
A/canine/CO/148902/2006 30-Oct-06 C2 Humane shelter  
A/canine/CO/3/2006 28-Apr-06 C3 CSU VTH 
A/canine/CO/224766/2006 24-May-06 C2 CSU VTH 
A/canine/WY/86033/2007 14-Feb-07 E3; C3 Humane shelter 
A/canine/CO/231256/2007 08-Mar-07 C6 Humane shelter  
A/canine/WY/86955/2007 27-Feb-07 E1; C3 Humane shelter  
A/canine/CO/2025974/2007 14-Mar-07 E1; C3 Humane shelter  
A/canine/CO/234550/2009 27-Feb-09 C6 CSU VTH 
A/canine/SC/89215/2009 05-Dec-09 E3 Humane shelter 
A/canine/CO/850078/2009 31-Dec-09 E3 Humane shelter  
A/canine/CO/861142/2010 03-Mar-10 E3 Humane shelter  
A/canine/CO/861997/2010 09-Mar-10 E3 Humane shelter  
A/canine/CO/863160/2010 20-Mar-10 E3 Humane shelter  
A/canine/CO/866907/2010 10-Apr-10 E3 Humane shelter  
A/canine/CO/884753/2010 21-Jul-10 C1 Humane shelter  
A/canine/CO/886050/2010 27-Jul-10 C3 Humane shelter  
A/canine/NY/6977983/2010 05-Sep-10 E3 Humane shelter  
A/canine/NY/12370090/2011 12-Feb-11 E4 Humane shelter  
A/canine/NY/13258337/2011 05-Jun-11 E3 Humane shelter  
A/canine/NY/13454104/2011 30-Jun-11 E1 Humane shelter  
A/canine/NY/13453967/2011 30-Jun-11 C1 Humane shelter  
A/canine/NY/3821631/2011 06-Jul-11 E3 Humane shelter  
A/canine/NY/13693247/2011 03-Aug-11 E1 Humane shelter  
A/canine/NY/13752393/2011 12-Aug-11 E3 Humane shelter  
A/canine/NY/13889381/2011 25-Aug-11 E3 Humane shelter  
A/canine/NY/13949315/2011 01-Sep-11 E1 Humane shelter  
A/canine/NY/13949306/2011 01-Sep-11 E2 Humane shelter  
*Passage used for sequencing. Either from cell culture (C) or embryonated chicken eggs (E). Number 
indicates passage.  





Figure 7-1: Neighbor-joining tree with 1000 bootstrap replicates for all published canine influenza virus 
(H3N8) full-length HA protein sequences. Labels are included for branches with over 50% bootstrap 
consensus. Asterisks denote isolates from humane shelters collected 2009-2011. 
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York/South Carolina and the Colorado CIV isolates cluster separately from one another. Although viruses 
from these two regions share eight of the original nine adaptations from EIV and emerging CIV identified 
by Payungporn et al.8, as well as the three HA substitutions reported by Rivallier et al.,106 there were an 
additional 11 amino acid differences among Colorado and New York CIV isolates (I58V, D/E77D, I112V, 
G/E124G, K172K/E, Y174F, V223I, T/I242I, M268I, G/D464N/D, and L496I). Interestingly, five of these 
eleven newly identified differences were within H3 antigenic regions (Table 7-3). Moreover, viruses 
isolated from within the Colorado region also appear to be evolving. Nine amino acid differences appear 
among the viruses isolated during early infections in Colorado and Wyoming (2006-2007) and the isolates 
collected during the shelter study (2009-2010): D/E77E, S/L107L, V112I, G/E124G, F174Y, G/R218G, 
T/I242I, G/D464D, and E479K. This last site is of particular interest as it was one of the earliest CIV 
substitutions identified.7,8 The MEME analysis revealed five sites exhibiting evidence of episodic 
diversifying selection at a significance level of p<0.1. These included H3 amino acid residues 107, 169, 
216, 453, and 464. Site 107 is likely involved in cellular immunity,179 while sites 169 and 216 are located 
in or near antigenic sites. Amino acid residues 453 and 464 are located on the highly conserved HA2 
subunit of the HA protein. 
 Antigenic variation in CIV isolates. Overall, there were eight amino acid residue substitutions 
within three antigenic sites (A, D, and E) among all the isolates (Table 7-3).  
Table 7-3: Amino acid differences within antigenic regions among early CIV and contemporary CIV 





Early FL CIV106 Early CO/WY 
CIV 
Recent CO CIV Recent NY/SC 
CIV 
75* E H H H Q 
124 A G G/E G G 
172 D K K K K/E 
174 D F F Y F 
216* D N N N N/H 
223 D V V V I 
242 D I T/I I I 
262* E T T T P 
*Sites previously identified7,8,106,108 
Due to suspected serum degradation issues and low numbers of positive samples from South Carolina 
(n=3) and Florida (n=4), only a few sera from each shelter were tested against all five antigens with HIA. 
Even with the limited data, however, several trends emerge (Figure 7-2). Although sera from the 
A/canine/WY/86033/2006-infected and Colorado shelter dogs have little variation among HIA titers 
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(± 1-log difference), samples from Florida, South Carolina and New York had 2- to 3-log differences 
among geometric mean titers. The older Colorado virus (A/canine/CO/224986/2006) and the New York 
isolate (A/canine/NY/6977983/2010) both induced higher antibody titers for all three groups, suggesting 
potential antigenic drift from the early CIV isolate (A/canine/FL/43/2004) and the Wyoming virus 
(A/canine/WY/86033/2007). Interestingly, the Florida sera also had higher geometric mean titers to the 
newer Colorado virus (A/canine/CO/863160/2010).  
 
DISCUSSION 
 Since the emergence of CIV nearly nine years ago, the virus has circulated in a number of dog 
populations, most notably in dogs residing in humane shelters.7,112 Indeed, CIV is routinely isolated from 
such facilities.106,108,131 Whether this is because there are actually more CIV infections in shelter dogs 
compared to non-shelter dogs or because there is more surveillance in this particular population is a 
matter under current study.170 Nevertheless, the frequent isolation of CIVs in shelter dogs presents a 
unique opportunity to characterize genetic evolution and antigenic variation of a relatively novel influenza 
A virus “in situ.” 
 It is evident from these studies and others106,108 that CIV is diverging into two genetically distinct 
clades: Colorado and New York. Although tempting to consider these Western and Eastern CIV clades, 
the lack of sequences from other geographical regions (e.g., South Carolina and Florida in the East and 
California and Texas in the West) makes such a designation premature. It is interesting that the recent 
       
 
Figure 7-2: Cross-reactivity (hemagglutination inhibition antibody titers) between canine influenza virus 
(CIV) H3N8 isolates and CIV-positive sera collected from dogs 2009-2012. Hemagglutination inhibition 
titers are shown as geometric (log2) means (±SEM) from dogs residing at the Colorado (n=6), Florida 
(n=2), and New York and South Carolina (n=6) humane shelters.  
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New York viruses and the one South Carolina isolate are more related to older CIVs isolated in Colorado 
and Wyoming than to the newer Colorado CIV isolates (Figure 7-1). Additionally, it appears that CIV has 
undergone several evolutionary “dead ends.” For example, isolates from Cheyenne Animal Shelter 
(A/canine/WY/86955/2007 and A/canine/WY/86033/2007), were collected several months after severe 
CIV outbreaks in Cheyenne caused the shelter to reportedly euthanize 70-80 dogs.180 These three CIVs 
do not appear to be closely related to any of the newer Colorado isolates. Instead, the recent Colorado 
CIVs are genetically similar to viruses isolated from dogs residing at animal shelters located in Fort 
Collins and Boulder, CO. In fact, all of the Colorado CIVs are nearer phylogenetically to the emerging 
Florida isolates (as previously reported106,108), while the New York shelter isolates appear to have evolved 
from the same ancestor as the Wyoming isolates from 2006-2007.  
 The MEME analysis found five sites in the HA coding region undergoing episodic diversifying 
selection: 107, 169, 216, 453, 464. Three of these sites (107, 169, 216) are located on the HA1 protein 
(HA sites 1 through 328), including one site located in an antigenic region, while two of these (453, 464) 
are on the highly conserved HA2 protein (HA sites 330 through 550). Substitutions at site 107 were 
reported in 2008 as a replacement of serine in the conserved EIV and early Florida CIV isolates by a 
proline in the A/canine/Jacksonville/2005 strain.8 However, recent isolates from both New York and 
Colorado show a leucine substitution at this site instead. Site 107 is part of a peptide region (105-140) 
that stimulates proliferation of T helper cells.179 Isolates substituting serine at position 107 change the 
amino acid from one with a polar uncharged side chain to either one with a secondary amine (proline) or 
one with a hydrophobic side chain (leucine). Such substitutions might result in steric and/or 
conformational changes of the peptide, resulting in lack of T-helper cell recognition, and, thus, reduced 
CIV-specific immune response. Likewise, mutations leading to conformational change at sites 216 
(antigenic region D) and 169 (near antigenic region D) might alter antibody-binding affinity. Interestingly, a 
P169L mutation was seen in two H3N2-vaccinated guinea pigs from post-challenge isolates,181 
suggesting a mutation at this site might be involved in immune escape.  The sites identified as 
undergoing selection pressure on the HA2 protein – HA 453 (HA2 site 124) and 464 (HA2 site 135) – 
contribute to protein stabilization before virion envelope and endosome membrane fusion.182 Additionally, 
although not identified as a site undergoing selection pressure, residue 479 is also located in this HA2 
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peptide region. The canine adaptation at site 479 (HA2 site 150)8,106,108 from glycine in EIV and emerging 
CIV to glutamic acid in 2005-2008 canine isolates has been observed before in human influenza H3 
viruses,183 and is in the same soluble region (HA2 38-175) as HA sites 453 and 463. It is conceivable that 
these three mutations might either hinder or help conformational stability of the HA2 protein before fusion 
of the viral and endosomal membranes, enabling release of viral ribonucleoproteins into the cytoplasm 
and subsequent virus transcription and replication. Further investigation into the role these sites play on 
CIV stability might aid our understanding of how CIV emerged from EIV to become a canine-specific 
influenza A virus.  
 With eight amino acid substitutions within three antigenic regions, antigenic drift might also be 
occurring for the newer CIV isolates. However, it is important to note that E124 (site A) was only observed 
in two of the viruses isolated after the Wyoming 2006 outbreak (A/canine/CO/231256/2007 and 
A/canine/WY/86033/2007). Other mutations seen in only a few isolates included two clinical samples from 
the CSU VTH with I242T (A/canine/CO/3/2006 and A/canine/CO/224766/2006) and two shelter CIVs with 
K172E (A/canine/SC/89215/2009 and A/canine/NY/13693247/2011). Therefore, five consistent 
substitutions were observed in either Colorado or New York isolates. In antigenic site D, two amino acid 
substitutions (N216H and V223I) were identified in the New York isolates – only one New York isolate 
(A/canine/NY/12370090/2011) shared the N216 motif with the Colorado isolates. Also within site D, 
another substitution (F174Y) was seen in the CIVs isolated from the Colorado shelter 2009-2010. For site 
E, two amino acid residue mutations were seen in the New York isolates (H75Q and P262T). Although HI 
assay results should be cautiously interpreted because of the small sample size and unknown CIV strain 
inducing serum antibodies, there is some serological evidence supporting antigenic drift of CIVs. For 
example, there was a four-fold HI titer difference for serum samples from New York between the 
A/canine/NY/6977983/2010 and A/canine/CO/863160/2010 antigens. It is interesting that the older 
Colorado strain (A/canine/CO/224986/2006) had a similar HI titer as the New York strain. The only amino 
acid residue from Table 7-3 common to the 2006-2007 Colorado and 2010-2011 New York isolates, that 
is not shared with the 2009-2012 Colorado isolates, is F174. The biochemical difference between 
phenylalanine and tyrosine is the polar side group (OH) on the latter. What conformation change this 
would cause in CIV has yet to be examined. 
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 As the analyses presented here are based on genomic and antigenic sites described for human 
and equine H3 influenza A viruses,82,83,166-168 it is possible that the CIV HA has different antigenic regions 
that have yet to be defined. Additionally, more research on CIV is warranted to confirm the structure of 
the CIV HA protein, map antigenic regions associated with virus neutralization and antigenic drift, and 
further investigate antigenic variation leading to CIV immune escape. This latter point is of particular 
import, as influenza vaccines are well recognized for inducing antigenic drift. Finally, one limitation of our 
study was the possible degradation of nasal swab samples between collection, transport, and processing. 
As samples were stored on-site at humane shelters before being shipped to the CSU laboratory, 
infectious virus might have been compromised, which could account for our low number of isolates. 
Future studies utilizing virus isolation may want to find a quicker, yet practical, protocol for sending 
samples to the laboratory soon after collection. 
 In conclusion, the findings reported here support previous studies106,108 that suggest CIV is 
diverging into two genetically distinct clades – Colorado and New York. More research is needed to 
determine how far geographically this divergence extends. Examination of 58 CIV HA nucleotide 
sequences isolated between 2003 and 2011 found five amino acid residues under selection pressure – 
one within an antigenic region. Additionally, a total of five amino acid changes were observed in two 
antigenic sites (D and E) for CIVs isolated from Colorado and New York humane shelters from 2009 to 
2011. Finally, although preliminary studies suggest that the New York clade is evolving into a distinct 
antigenic cluster, controlled experiments are required to determine true extent of antigenic drift occurring 
within circulating CIV. 
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CHAPTER EIGHT: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 The studies conducted here support the main hypothesis that CIV is being transmitted and 
maintained in U.S. dogs, which is further supported by the evolution of the canine-specific influenza A 
lineage. Additionally, these reports contribute several important findings to our understanding of CIV and 
its impact on dog populations: (1) Real-time RT-PCR assays should be used as a rapid test for detecting 
CIV and can minimize false negatives, allowing a more accurate representation of CIV infection in dogs. 
(2) Both CIV shedding and seroprevalence in the dog populations sampled, including from CIV-endemic 
and -epidemic shelters, are not nearly as high as first reported in racing greyhounds and New York and 
Florida shelters in 2004-2005, suggesting either there are other genetic or environmental factors 
contributing to fatal CIV infection or there are some host-immune response mechanisms limiting severe 
CIV disease in some dogs. (3) Despite low CIV prevalence, control measures (i.e., minimizing dog 
interactions within a facility and use of an effective vaccine) should still be implemented for at-risk dogs, 
such as dogs in boarding facilities, attending canine day care, and residing in shelters. (4) Additionally, 
CIV, like other influenza A viruses, appears to be a disease of space and time. Therefore, modeling could 
be helpful for predicting future CIV outbreaks. (5) Finally, CIV is evolving into two genetically distinct 
clades, one of which is antigenically different from previous CIVs. Controlled experiments are required to 
determine true extent of antigenic drift occurring within circulating CIV and, if necessary, CIV vaccines 
should be updated accordingly. 
 
Future Directions 
 Although there are many follow-up studies that may support the evidence presented in this 
dissertation, efforts would be better served if future research is focused on three specific areas: (1) the 
efficacy of the CIV vaccination in a field setting, (2) understanding the CIV-dog pathogen-host 
interactions, and (3) comparing what we know about H3N8 CIV in the United States to emerging H3N2 
IAV in dogs in southeastern Asia.  
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 For the first, it is interesting that in several studies dogs that were reported to be vaccinated did 
not seroconvert. This observation has been noted in laboratory experiments with sera from six fully-
vaccinated dogs as well (unpublished data). Naturally, there are several possibilities for these results: the 
dogs were not vaccinated or not vaccinated correctly, the samples were taken before the onset of the 
host immune response, no vaccine booster was given, or the vaccine does not induce a detectable 
antibody response. Even vaccinates in the study conducted by the vaccine manufacturer111 report a mean 
HI titer of 138 (it is stated to be a geometric mean but this is likely an error as pre-vaccination titers were 
reported as <10). Although follow-up studies demonstrate more convincingly that the vaccine reduced 
severity of illness in dogs co-infected with CIV and Streptococcus equi spp. zooepidemicus,184 the lack of 
seroconversion seen in field samples needs to be further investigated. The biggest question at hand is 
whether or not vaccinated dogs are protected against CIV. While true that the vaccine manufacturer 
found lessened disease severity in their experiments, both studies were conducted in pups six to ten 
weeks old. Without controlled and field experiments to examine the efficacy of the CIV vaccine in adult 
dogs, it is difficult to recommend its use outside at-risk dog populations (such as shelter, day care, and 
boarding dogs). Even then, the gap of knowledge regarding its efficacy tempers enthusiasm for the 
vaccine. 
 The second focus of future research, understanding the CIV-dog pathogen-host interaction, 
relates to how an IAV jumped the species barrier. Studies in this area might also shed light on why CIV-
infection was so fatal in the beginning of the outbreak. Results from Appendix A and Quintana et al.109 
show that members of our laboratory have developed an in vitro cell culture system (respiratory epithelial 
cells grown at the air-fluid interface) that mirrors infection and replication of EIV and CIV observed in the 
equine and canine host. Using this system, it is possible to determine cell signals inducing interferon and 
other cytokine production during early respiratory infection.185 Such experiments with equine herpes virus-
infected equine respiratory cells have been underway, and EIV infection experiments were recently begun 
to examine mRNA expression and protein production during early IAV infection. A similar experiment 
using canine respiratory epithelial cells from various dog breeds and different CIV isolates might answer 
the question of why greyhounds were particularly afflicted with high case fatality rates. Even more 
promising is what the mRNA and protein expression comparisons of chemokines induced by EIV- and 
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CIV-infection might reveal. Research here (Appendix A) and elsewhere105 suggest that receptor binding 
preference is the same for both CIVs and EIVs. Determining what happens after viral entry in early 
infection, therefore, is a logical next step for trying to elucidate how an EIV was able to sustain infections 
in dogs. 
 Finally, it has been reported that an avian IAV H3N2 is being transmitted among dogs in South 
Korea and China.186-188 Experimentally, avian IAV H3N2 is able to be transmitted from infected dogs to 
susceptible dogs via direct contact.189 Transmission among dogs in an experimental setting, however, 
does not necessarily mean there is a new CIV emerging. A major criterion for designation of a host-
specific IAV lineage is sustained transmission among the new host species and subsequent 
maintenance. Consistent amino acid substitutions within the proteome would also suggest adaptation to a 
new host. Although more surveillance studies are needed to confirm sustained transmission, viruses from 
6 of 13 nasal swabs collected during an IAV outbreak were isolated and found to contain the same 
W222L mutation found in CIV H3N8 isolates.188 Additionally, 19% (68/361) of farmed dogs in South Korea 
were seropositive on anti-NP ELISA.187 It thus appears that sustained transmission of an avian IAV is 
occurring and that there are amino acid adaptations to the canine host. However, further complicating 
designation of a H3N2 canine-specific IAV is the fact that cats have also been reported to be infected.190 
Despite this caveat, the transmission of avian IAV in dogs and cats is a great opportunity for research to 
re-examine the emergence of CIV H3N8 to find any similarities and differences between the two IAVs, 
both genetically or epidemiologically. 
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APPENDIX A: COMPARISON OF THE INFECTIVITY AND TRANSMISSION OF CONTEMPORARY 
CANINE AND EQUINE H3N8 INFLUENZA VIRUSES IN DOGS 
 
INTRODUCTION 
 Due to the partial host range restriction of influenza A viruses, transmission of an influenza virus 
from one species to another is relatively rare. However, such cross-species transmission events do occur 
and have generated severe disease outbreaks in the new host species. The 1918 “Spanish Flu” is a 
classic example of cross-species transmission with devastating results, as the influenza virus that caused 
the pandemic was likely transmitted directly from birds to humans.191 Therefore, understanding the 
molecular mechanisms that allow these viruses to cross the species barrier and adapt to new hosts is 
crucial for identifying influenza viruses that could potentially threaten both human and animal health. 
While evidence has accumulated over the years indicating contributions by all eight gene segments,87-
90,192-196 the examination of the impact of individual viral proteins to host range restriction is complicated 
by several factors. For instance, mutations often occur in multiple gene segments during the process of 
virus adaptation to a new species,194,197-199 and, while some of these mutations may indeed reflect 
adaptation of the virus to the new host, others may be introduced in response to host immune pressure or 
they might simply represent spurious mutations. Furthermore, cross-species transmission of influenza is 
frequently preceded by an exchange of gene segments between two viruses (“genetic reassortment”), 
resulting in even greater genetic variability.200-202  
 Historically, dogs were not considered to be natural hosts for influenza despite occasional 
transmission of viruses to dogs from humans,95,96 birds,186 and horses.9,10 In 2004, however, influenza 
was reported in racing greyhounds and the virus has since been maintained in dog populations 
throughout the U.S.7,8 Phylogenetic analyses reveal that canine influenza virus (CIV) isolates are closely 
related to, and evolved from, the equine influenza virus (EIV) H3N8 Florida sublineage.7 Amino acid 
sequence analyses demonstrate that the CIV isolates consistently differ from contemporary equine-
lineage H3 viruses at five amino acid residues in the hemagglutinin protein (HA), including a tryptophan 
(W) to leucine (L) substitution at residue 222 located near the receptor binding pocket7,8 and seven amino 
acid mutations within the internal genes.7,8,203 Moreover, as the equine H3N8 virus was transmitted to 
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dogs without prior genetic reassortment,7 it is possible that specific constellations of gene segments do 
not play a role in controlling the equine-to-canine species barrier.  
 Interestingly, results from two recent studies demonstrate that CIV isolates are unable to infect, 
replicate, and spread among susceptible horses.105,109 Moreover, inoculation of horses with canine 
influenza virus did not result in clinical disease in either study, indicating the existence of genetic 
differences in the horse that resulted in an “all or nothing” infection when inoculated with EIV or CIV, 
respectively. To determine whether contemporary equine viruses are similarly restricted in dogs, we 
evaluated the infectivity and transmission of a recent EIV isolate in dogs. Additionally, we sought to 
determine the receptor binding affinity of recent CIV isolates to examine whether the HA W222L mutation 
has resulted in an alteration in receptor binding affinity of canine isolates. 
 
MATERIALS/METHODS 
 Influenza Viruses. For the binding assays, field isolates of A/equine/CO/10/07 (Eq/CO) (H3N8), 
A/canine/CO/224986/06 (Ca/CO-1) (H3N8), A/canine/WY/86033/07 (Ca/WY) (H3N8), 
A/canine/CO/2025974/07 (Ca/CO-2) (H3N8), A/equine/KY/1/81(H3N8) (Eq/KY; provided as allantoic fluid 
stock from the University of Wisconsin-Madison’s Influenza Virus Repository), and A/Sydney/05/97 
(H3N2) (A/Syd; provided as allantoic fluid stocks from the CDC) were cultivated in embryonated chicken 
eggs or MDCK cells as previously described.135,204 The Eq/CO and Ca/WY isolates were used for 
inoculation of dogs in the in vivo challenge and were passaged in 10-day old embryonated chicken eggs 
and MDCK cells. All gene segments from the Eq/CO and Ca/WY isolates used for inoculation were 
sequenced and compared with their respective parental virus sequences. 
 Sequence Analyses. To confirm the presence of the amino acid differences between the equine 
and canine H3 viruses, the full-length protein coding regions of the HA genes of Eq/CO, Ca/CO-1, 
Ca/WY, and Ca/CO-2 were amplified by reverse transcriptase (RT)-PCR, as previously described.205 
Sequence comparisons of these viruses, as well as published equine and canine influenza virus H3 
sequences (obtained from the BLAST database [http://blast.ncbi.nlm.nih.gov]), were made using Clustal 
W alignment (http://www.genome.jp/tools/clustalw/).  
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 Equine and Canine Influenza Challenge. Twenty 12-month old dogs were obtained from a 
commercial laboratory animal vendor and assigned to one of five groups: two inoculation groups (five 
dogs/group), one mock-inoculation control group (four dogs/group), or two sentinel groups (three 
dogs/group). Study groups were housed separately in nearby research facilities. Serum samples from 
each dog were confirmed to be CIV- and EIV-negative using hemagglutination inhibition (HI) assay before 
inoculation. The animals were examined prior to inoculation and found to be clinically healthy and in good 
body condition. Dogs were maintained in accordance with guidelines of the Colorado State University 
Research and Animal Resources Committee. One dog from the Ca/WY inoculation group was withdrawn 
due to behavioral issues with other dogs in the group. Inoculated groups were infected with either Ca/WY 
or Eq/CO via intra-tracheal aerosol exposure with 107 50% tissue culture infectious dose (TCID50) after 
they were pre-medicated with midazolam and butorphanol, anesthetized by intravenous administration of 
4-6 mg/kg of propofol, and intubated. Sentinel groups were introduced and housed with each infection 
group two days post inoculation. Before initiation, this study was reviewed and approved for conduct by 
the Colorado State University Institutional Animal Care and Use Committee. 
 Clinical Scoring. For 14 days following inoculation, each dog was observed 20 minutes for 
clinical signs of infection. Clinical scoring consisted of numerical scoring based on observations of 
lethargy, anorexia, sneezing, coughing, ocular and nasal discharge, respiratory rate, and temperature, as 
previously described.109 Briefly, parameters assessed included general attitude, cough, nasal discharge 
(these were quantified on a scale of 0 to 3, with 0 indicating a clinically normal animal and 3 indicating a 
severely abnormal animal), food intake (with 0 indicating that the animal was eating and 1 indicating that 
the animal was anorexic), respiratory rate (number of breaths per minute), and rectal temperature.  
 Assessment of Viral Shedding. Nasal swabs were collected daily one day before and for 21 
days after inoculation. The swabs were placed in 1 ml of viral transport medium and stored at -80°C until 
they could be processed for influenza virus isolation. RNA was extracted from 140µl of viral transport 
medium using the QIAamp® Viral RNA Mini Kit (QIAGEN, Hilden, Germany). Real-time RT-PCR assays 
were performed using previously established cycling conditions.206 Briefly, for virus quantification, purified 
full-length influenza A matrix (M) gene RNA was used as a standard for calibration of the M gene copy 
number. Each nasal swab sample was run in duplicate. Negative controls included neat transport medium 
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processed as for the nasal swab specimens. The positive controls consisted of 101 to 106 TCID50 of 
A/canine/CO/224986/06 in distilled water.  
 Serological Analysis. Sera from blood samples taken from inoculated dogs on days 7, 12, and 
19 post inoculation and from sentinel dogs on days 7, 12, and 19 post introduction were treated with 
receptor destroying enzyme prepared from Vibrio cholera before they were tested for hemagglutination 
inhibiting antibodies via HI assay.135 Briefly, two-fold serial dilutions of sera were mixed with four 
hemagglutination units of Eq/CO and Ca/WY. The assays were developed by adding 0.5% (vol/vol) 
chicken red blood cells, and the HI antibody titers were read as the reciprocal of the highest dilution 
causing complete inhibition of hemagglutination. 
 Virus Binding Affinities. To account for any cell-culture induced mutations, sialic acid (SA) 
binding affinities of both MDCK cell- and embryonated chicken egg-grown stocks of Ca/CO-1, Ca/WY, 
Ca/CO-2, and Eq/CO were determined using a solid-phase binding assay,30,31 with slight modification of 
the original protocol to equilibrate the viruses assayed to ~20,000 matrix gene copies.207,208 The 
biotinylated glycopolymers tested included Neu5Acα2-3Galβ1-4Glc-PAA[1000]-biot (2,3SL), Neu5Acα2-
3Galβ1-4GlcNAcβ-PAA[1000]-biot (2,3SLN), Neu5Acα2-6Galβ1-4GlcN-PAA[1000]-biot (2,6SL), and 
Neu5Acα2-6Galβ1-4GlcNAcβ-PAA[1000]-biot (2,6SLN) (Syntesome, Moscow, Russia). All polymers had 
a molecular weight of 1MDa and were diluted 1:500 prior the experiments. Both fetuin- and non-fetuin-
coated plates were utilized, as conditions for performing the solid-phase binding assay have not yet been 
described for use with CIV and EIV isolates. Each assay was performed four times in duplicate, including 
positive (Eq/KY and Eq/CO for SAα2,3 binding and A/Syd for SAα2,6 binding) and negative (working 
buffer) controls.  
 Sialic Acid Staining. To investigate whether the receptor binding specificity of the canine viruses 
reflect complementary SA receptor expression in the respiratory tract of dogs, we stained sections of 
canine nasal mucosa, larynx, trachea, bronchus, and lung tissue with SAα2,3-gal-specific and SAα2,6-gal 
specific lectins.35,209 Fluorescein isothiocyanate (FITC)-labeled Sambucus nigra lectin (Vector 
Laboratories, Burlingame, CA) was used to indicate the presence of SAα2,6-gal, while biotinylated 
Maackia amurensis lectin (Vector Laboratories) detected with Alexa Fluor 594-streptavidin complex 
(Molecular Probes/Invitrogen, Carlsbad, CA) was used to stain SAα2,3-gal receptors. Tissues were 
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counterstained with DAPI (4,6-diamidino-2-phenylindole). Equine airway tissues collected from the same 
anatomical locations were included in the staining procedure to serve as controls, as the pattern of SA 
expression in the horse trachea has been previously defined.37 
 Statistical Analyses. To analyze the overall mean differences in the levels of virus nasal 
shedding, HI antibody titers, clinical scores, and body temperatures between the infected groups and the 
mock-inoculated controls, we performed generalized estimating equations, as previously described.109 
Briefly, adjusted mean differences were clustered on repeated measures for each outcome. Other 
outcome variables (except clinical scores, which were ranked prior to analysis) were log transformed to 
meet the major assumptions of linearity and normality. For data transformation, HI antibody titers and M 
gene copy numbers with values of zero were converted to one. For the receptor-binding assays, 
dissociation constants (KD) for viruses were determined by linear regression analysis of Scatchard plots 
performed using Prism software (GraphPad, La Jolla, CA).  
 
RESULTS 
 For the in vivo challenge, both Ca/WY and Eq/CO inoculated dogs showed little to no evidence of 
clinical disease. None of the dogs had a temperature 
over 103°F during the course of the study. One 
sentinel dog and one inoculated dog in the Ca/WY 
group were observed coughing, sneezing, and with 
serous ocular discharge between days 5 and 12 post 
inoculation (between days 3 and 10 post introduction 
for the sentinel). From the Eq/CO group, one 
inoculated dog had periodic anorexia and sneezing 
between days 3 and 13 post inoculation and one 
sentinel showed signs of lethargy on day 3 post 
introduction. Although little clinical disease was 
evident, serologically, 4/4 (100%) of the Ca/WY-




Figure A-1: The M gene copy number mean 
± SEM of virus shed in nasal passages for 
mock-inoculated (), Ca/WY-inoculated (▲), 
Ca/WY sentinel ( ), Eq/CO-inoculated ( ), 
and Eq/CO sentinel ( ) dogs. The minimum 
detection level of the real-time RT-PCR was 
1000 M gene copies per reaction 
corresponding to 103 TCID50 of Ca/CO-1 and 
is represented by the dashed line. 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inoculation (mean titer 1:896 ± 368 SEM) and 2/3 (67%) of the CIV-infected dog sentinels had positive HI 
assays (mean titer 1:1365 ± 557 SEM) by day 12 after introduction. Of the Eq/CO-inoculated dogs, 80% 
(4/5) seroconverted (mean titer 1:461 ± 152 SEM) by day 12 after inoculation, although none of the 
sentinels had a positive HI assay through day 21. Real-time RT-PCR data resemble the HI data for the 
inoculated dogs from both groups (Figure A-1). Interestingly, influenza virus was not detected by real time 
RT-PCR in neither the Ca/WY nor the Eq/CO sentinel groups. The negative controls did not shed 
detectable virus, as expected. Generalized estimating equations revealed that, compared to the negative 
controls, only nasal shedding and antibody titers were significantly higher for both the Ca/WY and Eq/CO 
inoculated dogs (Table A-1) compared to the mock-inoculated negative 
controls.
 
 With the exception of A/Syd, which bound only to fetuin-coated plates (as previously described for 
human influenza viruses30,31), all equine and canine viruses bound only to non-fetuin-coated plates. As 
the 2,3SL polymer demonstrated similar binding as the 2,3SLN polymer and the 2,6SL polymer is not 
believed to be an suitable analog for the human influenza virus receptor,210 only the 2,3SLN and 2,6SLN 
data are presented here for appropriate comparisons. Based on calculated approximate KD values (where 
lower values represent higher binding affinity), Eq/CO and Eq/KY demonstrated the anticipated binding 
preference for SA SAα2,3-gal (2,3SLN) compared to 2,6SLN (Figure A-2a). In fact, nearly no binding to 
SAα2,6-gal (2,6SLN) was detected. Likewise, the SAα2,6-gal control (A/Syd) preferred 2,6SLN as 
expected (Figure A-2b). Interestingly, Ca/CO-1, Ca/WY, and Ca/CO-2 showed the same binding 
preference as the equine viruses, which was characterized by higher affinity for SAα2,3-gal (2,3SLN) and 
only minimal binding to 2,6SLN (Figure A-2c). Table A-2 lists the KD values for all the viruses tested with 
the 2,3SLN and 2,6SLN polymers. Because there was no detectable binding (NDB) to the 2,6SLN  
Table A-1: Statistical analyses of Ca/Wy and Eq/CO challenge dog groups compared to mock-
inoculated negative controls. 
 Temperature Clinical Score Nasal Shedding HIA Titer 
Ca/WY Inoculated P=0.077 P=0.460 P=0.001* P<0.001* 
Ca/WY Sentinel  P=0.608 P=0.130 P=0.704 P=0.185 
Eq/CO Inoculated  P=0.155 P=0.103 P=0.018* P<0.001* 









Figure A-2: α2,3SLN and α2,6SLN polymer binding by equine influenza (a), human influenza (b), and 
canine influenza (c) isolates were determined using a solid-phase binding assay and linear regression 
analysis. 
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polymer for the canine and equine isolates upon linear regression of Scatchard plots, we were unable to 
determine their KD values. However, viruses that bound to the 2,3SLN polymer demonstrated low KD 
values, indicating that they had high binding affinities for SAα2,3-gal. Again, as expected, A/Syd had a 
human type receptor binding preference with a higher relative affinity for SAα2,6-gal than for SAα2,3-gal 
receptor analogues. The staining results revealed that SAα2,3-linked receptors (indicated by the red 
staining in Figure A-3) was the predominant receptor expressed on the airway epithelial cells of the upper 
respiratory tract in both horses and dogs. Furthermore, SAα2,3-gal was the primary receptor expressed 
on the respiratory epithelium throughout the trachea (upper, middle, and lower) and bronchus in both 
species. This is consistent with recently published data 9 that also found a predominance of SAα2,3-gal in 
the canine trachea. In contrast, alveoli demonstrated both red and green staining, suggesting that both 
SAα2,3-gal and SAα2,6-gal receptors are expressed deep within the respiratory tract of dogs and horses. 
 Review of the HA amino acid sequences indicated that the five amino acids previously described 
as possible dog adaptation mutations (N54K, N83S, W222L, I328T, N483T)7,8 have been conserved in 
the canine viruses cultivated for use in these studies. In contrast, Eq/CO shared the previously described 
equine H3 consensus sequence.7 Sequences of the Ca/WY and Eq/CO isolates used for inoculation did 
not differ from their respective parental virus sequences. 
 
Table A-2. Approximate binding affinity of equine and canine influenza viruses  
 
 
2,3 SLN Polymer  2,6 SLN Polymer 
Virus App KDa R2 b App KD R2 b 
Eq/KY 11 .96 NDBc - 
Eq/CO 5 .99 NDBc - 
Ca/CO-1 5 .99 NDBc - 
Ca/CO-2 2 .94 NDBc - 
Ca/WY 2 .95 NDBc - 
A/Syd 139 .97 10 .99 
a Approximate dissociation constant (KD) values are from one representative experiment. Lower KD 
values represent a higher binding affinity for that polymer (KD is expressed in nM-1 sialic acid). 
Repeated experiments yielded similar results. 
b R2 = coefficient of determination. 
c NDB = no detectable binding. 
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Figure A-3: Equine and canine respiratory tissues for the upper respiratory tract (URT) and lower 
respiratory tract (trachea, lung) stained with lectins specific for sialic acids with α2,6 - and α2,3-
linkages. Green staining: reaction with fluorescein isothiocyanate (FITC)-labeled Sambucus nigra 
lectin (Vector Laboratories, Burlingame, CA) indicating the presence of sialic acids linked to galactose 
by an alpha2,6-linkage (SAα2,6-gal). Red staining: reaction with biotinylated Maackia amurensis lectin 
(Vector Laboratories) (detected with Alexa Fluor 594-streptavidin complex; Molecular 
Probes/Invitrogen, Carlsbad, CA), indicating the presence of SAα2,3-gal Tissues were counterstained 




 Our results demonstrate that a recent EIV isolate is able to infect and replicate in the canine host. 
This was evidenced by both CIV- and EIV-inoculated dogs testing positive for antibodies on HI assay and 
shedding detectable virus on real time RT-PCR. In contrast, recent studies conducted by members of our 
laboratory,109 as well as others,105 have revealed that CIV has virtually lost the ability to infect, replicate, 
and spread among susceptible horses. Interestingly, a similar pattern of infectivity and replication has 
been observed in primary equine and canine respiratory epithelial cells (RECs) inoculated with both CIV 
and EIV isolates.109 In these experiments, CIV and EIV isolates were able to infect and subsequently 
replicate in canine RECs, while the EIV isolate was better able to infect and replicate in equine RECs 
compared to the CIV isolate. Taken together, the results from these recent studies suggest there is 
apparent host range restriction for CIV in horses, which is not been observed for EIV in dogs. One well-
described determinant for influenza virus species-specificity that might explain CIV host range restriction, 
and one which we wished to examine in these studies, is receptor-binding preference. While evidence 
suggests that the amino acid sequence of the receptor-binding pocket (formed in part by residues 224 
through 228 in H3 viruses) modulates the affinity of influenza viruses for specific SA receptors,211 amino 
acid residues at other sites in the HA protein may also determine the receptor specificity of influenza 
viruses. For example, recent research indicates that the amino acid residue 222 in human and avian H3 
viruses might serve as a key determinant for binding of human receptor analogs by the HA protein.212 
Indeed, early CIV studies postulated that, in dogs, the W222L CIV substitution might play a role in 
maintenance of influenza by modulating receptor-binding function.7,8  
 Interestingly, our solid-phase binding assay results demonstrate that CIV isolates, like EIV 
isolates, have a higher affinity for SAα2,3-gal compared to SAα2,6-gal. This preference is mirrored by a 
predominance of SAα2,3-linked receptors in the upper respiratory tract and trachea of dogs. The finding 
that CIV has a similar overall receptor-binding preference as its equine H3 ancestor might explain the 
natural transmission of equine influenza viruses to dogs that occurred on at least three separate 
occasions.7,9,10 Our in vivo results confirm EIV is still capable of infecting and replicating in dogs. 
Transmission of EIV from infected to sentinel dogs would further indicate ability of EIV to be maintained in 
dogs. However, our results show no influenza infection in sentinels introduced to the EIV-inoculated 
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group, although a similar study found dogs could be sub-clinically infected with EIV when introduced to 
EIV-infected horses.110 In spite of these conflicting reports, it still remains unclear why only one of the 
previous transmission events and none of the experimental studies resulted in the formation of a stable 
influenza virus lineage within dog populations.  
 This lack of dog-to-dog EIV transmission might be explained by the biochemical structure of the 
SA receptor itself. For example, respiratory epithelial cells in the equine trachea have been found to 
express mostly α2,3-linked N-glyconeurominic (Neu5Gc) SA receptors rather than N-acetylneurominic 
(Neu5Ac) SA receptors.95 Another recent study done by Yamanaka et al.105 in which solid-phase binding 
assays were conducted using Neu5Gc and Neu5Ac analogues, suggests there is a EIV binding 
preference for the Neu5Gc SA receptor compared to the Neu5Ac SA receptor moiety. However, in the 
same study, the CIV isolate tested did not appear to have a preference for either the Neu5Ac or Neu5Gc 
analogue,105 leaving the question of CIV host range restriction in horses unanswered and, therefore, 
leading us to propose other determinants of CIV species-specificity. 
 Of these potential determinants of host range, the HA protein must still be considered as it also 
mediates fusion of the viral envelope with the endosomal membrane of the host cell.22 To mediate fusion, 
the stalk portion of the HA has to undergo complex refolding.22 While the specific role of the N83S 
substitution has yet to be determined, residue 83 is part of an extension from the central triple-stranded 
coiled coil (made up of H3 HA residues 76-105), which repositions and exposes the fusion protein when 
the HA protein is subjected to low-pH.44 The substitution of a positively charged amino acid (asparagine) 
with a hydrophilic residue (serine) might change the protein structure, possibly altering HA refolding. 
Similarly, the substitution of threonine (a polar residue) for isoleucine (a nonpolar residue) at the HA 
cleavage site (residue 328)44 may have affected host protease-viral protein interactions, thereby 
modulating efficacy of membrane fusion and viral entry into host cells. 
 Beyond the HA gene, it is possible that mutations in other RNA segments could account for virus 
adaptation to dogs. In this regard it is interesting that sequence alignments revealed three mutations in 
the PA (residues 33, 388, 675) and one mutation in the PB2 (residue 374) proteins that consistently 
differentiate the canine from the equine consensus sequences. As these mutations are located at 
previously defined functional sites of the PA (PB1 binding site, protease and cap-dependent ribonuclease 
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regions) and the PB2 (PB1 binding site),213 it is possible that these substitutions are important for efficient 
replication of CIV particularly in the canine host. Further reverse genetics and site-directed mutagenesis 
studies are warranted to address the roles each gene segment plays in CIV species-specificity. 
 In conclusion, the results of the studies described here contribute to our overall knowledge of 
EIV/CIV species-specificity. We have shown that EIV is still capable of infecting dogs, although we could 
not show that EIV is transmitted among dogs in an experimental setting. Conversely, as reported, the 
opposite is true for CIV in horses.105,109 Additionally, our in vivo studies detail similar findings from a 
previous in vitro experiment where both CIV and EIV were able to infect and replicate in primary canine 
RECs.109 Combined with data that show a clear preference of equine RECs for EIV, we believe we have 
developed an in vitro model on which future host range studies can be based. This model might be useful 
in examining host-pathogen interactions that contribute to CIV transmission and maintenance within the 
US dog population.  
 
